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ABSTRACT 
 
The adverse health associations reported for red meat may be attributed to 
increased saturated fatty acid (SFA) intake. This project aims to evaluate the effects of 
beef fatty acid composition and lean beef on atherosclerotic cardiovascular disease 
(ASCVD) risks in two healthy populations. 
Study 1: 
Twenty-five normocholesterolemic men consumed in random order: 5-114 g, 
24% fat beef patty/wk for 5 wk of both low (M:S = 0.71)  and high monounsaturated 
fatty acid (MUFA) (M:S = 1.10) beef patties (~40 EN% fat diet). Increased beef 
consumption had no effect on circulating adipokines, homocysteine, paraoxonase1 
(PON1) activity, HDL density distribution and HDL3 apolipoprotein composition. 
Independent of fatty acid composition, beef consumption reduced HOMA-IR scores and 
the pro-inflammatory 5-keto-eicosatetraenoic acid (5-KETE) in HDL (P <0.05). The 
changes were positively correlated with baseline HDL-C and negatively correlated with 
baseline HDL EPA status respectively (P <0.05). Overall beef consumption increased 
HDL3 sphingosine-1-phophate (S1P) (P <0.05) and this change was negatively 
correlated with baseline triglyceride, total cholesterol, LDL-C and HDL3 ApoE (P 
<0.01).  
Study 2: 
Twenty-seven mildly hypercholesterolemic subjects consumed in random order: 
Healthy American diet (HAD), Dietary Approaches to Stop Hypertension (DASH), Beef 
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in an Optimal Lean Diet (BOLD) and BOLD plus extra protein (BOLD+) (20, 28, 113, 
153 g lean beef/d, respectively, all diets ~30 EN% fat) for 5 wk. The BOLD+ diet 
reduced absolute and fractional abundance of small LDL4 (P <0.05) relative to HAD. 
Baseline HOMA-IR was strongly associated with LDL4 responsiveness to the DASH (P 
= 0.003) and BOLD diets (P = 0.018). LDL4 decreased after the BOLD (P = 0.003) and 
BOLD+ (P = 0.046), but not DASH (P = 0.069) diets in the low baseline HOMA-IR 
group. The high baseline HOMA-IR group tended to show favorable changes in LDL4 
only after the BOLD+ diet (P = 0.078) with a significant dietary effect observed (P = 
0.013).  
Our studies showed that individual response to beef intervention, regardless of 
beef fatty acid composition or total fat, is influenced by baseline health status. In healthy 
individuals, increased beef consumption may have a favorable effect on ASCVD risk 
factors.  
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Introduction 
The inverse association of high-density lipoprotein cholesterol (HDL-C) 
concentration with atherosclerotic cardiovascular disease (ASCVD) is well established 
in clinical and epidemiological investigations. The Framingham Heart Study and the 
Prospective Cardiovascular Münster Study showed that for every 1.0 mg/dL increase in 
HDL-C, ASCVD risk decreases by 2-3% (1). In the National Cholesterol Educational 
Program Adult Treatment Panel III (NCEP ATP III) guidelines, a HDL concentration of 
<40 mg/dL is defined as an independent risk factor for ASCVD (2). As a result, 
increasing attention has been focused on raising HDL-C concentration as a strategy to 
prevent ASCVD. However, large clinical trials to increase HDL-C through 
pharmacologic agents show no clear ASCVD risk reduction with HDL-C concentration 
increases. A meta-analysis of 9,959 subjects drawn from niacin trials showed that 
elevation in HDL-C by niacin was not associated with reduced ASCVD risk (3). In large 
clinical trials, the improvement in HDL-C by cholesteryl ester transfer protein (CETP) 
inhibitor torcetrapib also failed to show preventive effects on atherosclerotic progression 
(4). Further, the recent dal-ACUTE trial demonstrated the dissociation between 
pharmacologically induced elevation in HDL-C and HDL protective function in acute 
coronary syndrome patients (5). In plasma, HDL particles serve as a platform on which 
rapidly to assemble and disassemble proteins and lipids. Accumulating evidence showed 
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that inflammation and oxidative stress are crucial modulators of HDL proteome and 
lipidome (6-8). The inability of HDL-C raising therapies have shed new insights into the 
complexity of HDL composition and function. Consequently, the research focus on 
HDL-C has now started shifting towards alternative metrics of HDL such as particle 
size, subclass distribution, and HDL functionality.  
Disease development and HDL functionality 
Atherosclerosis is an inflammatory process that is initiated in part by the 
presence of oxidized LDL in the artery wall, followed by endothelial dysfunction, 
recruitment of monocytes and formation of foam cells (9). Historically, the athero-
protective potential of HDL is attributed to its role in reverse cholesterol transport 
(RCT). This process promotes cholesterol efflux from peripheral tissues and most 
importantly, macrophage cells and returns cholesterol to liver to be metabolized or 
reutilized. As the HDL research moves increasingly toward functionality, other 
important athero-protective mechanisms have been uncovered. HDL can prevent the 
generation of reactive oxygen species (ROS), reduce the oxidation of phospholipids and 
inhibit the pro-inflammatory actions of minimally modified LDL. The anti-oxidant 
property of HDL is mostly attributed to its anti-oxidant enzymes including paraoxonase 
(PONase), ApoA-I, and platelet-activating factor acetylhydrolase (PAFAH) (10, 11). For 
anti-inflammatory protection, functional HDL inhibits the expression of monocyte 
chemotactic protein 1 (MCP-1) in vascular smooth muscle cells (VSMCs), promotes 
endothelial cell barrier integrity and prevents the recruitment of pro-inflammatory cells. 
Many anti-inflammatory activities of HDL have been shown to be mediated by its 
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sphingosine-1-phosphate (S1P) content and the activation of S1P G-protein coupled 
receptors (12, 13). There is also evidence that HDL can effectively downregulate Toll-
like receptor signaling by disrupting lipid raft formation (14) and by inducing the 
transcriptional regulator activating transcription factor 3 (ATF3) in immune cells (15). In 
addition, HDL can promote vasodilation via nitric oxide synthase (NOS) activation (16, 
17) and can attenuate apoptotic intracellular signaling in endothelial cells (18).  
HDL metabolism 
Plasma HDL is a heterogeneous group of small discoid and spherical particles.    
HDL particles are initially produced as lipid-poor ApoA-I by the liver or intestine (19) 
and immediately lipidated via ATP binding cassette transporter A1 (ABCA1) mediated 
cholesterol and phospholipid (PL) efflux, forming discoidal nascent pre-β HDL (20, 21). 
Phospholipids from lipoprotein lipase (LPL) hydrolyzed triglyceride-rich lipoproteins 
(TRL) present another important lipid source for nascent HDL (22). These nascent HDL 
particles are excellent substrates for lecithin:cholesterol acyltransferase (LCAT), that 
esterifies a fatty acid from phosphatidyl-choline (a.k.a. lecithin) to cholesterol to form 
cholesterol ester (CE) and lysophosphatidyl choline (23). Cholesterol esters are highly 
hydrophobic and migrate into the core of HDL, resulting in the core expansion of 
discoidal HDL and generation of spherical mature HDL. Small spherical HDL, known as 
HDL3, further acquires cholesterol via ATP binding cassette transporter G1 (ABCG1) 
and scavenger receptor class B type I (SR-BI) from peripheral tissues and forms large 
spherical HDL, known as HDL2 (24, 25). The particle size and composition of HDL are 
constantly remodeled by various cell surface transporters, lipid transfer proteins and 
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lipases. Cholesteryl ester transfer protein (CETP) transfers HDL-C to TRL in exchange 
for TG and generates TG-rich HDL (26). Phospholipid transfer protein (PLTP) promotes 
the net transfer of PL from TRL to HDL as well as the exchange of PL between them 
(27). PLTP also acts as a conversion factor, converting HDL3 into larger and smaller 
HDL particles (28).  Further, HDL particle size can be reduced through the actions of 
hepatic lipase (HL), and endothelial lipase (EL) and to a lesser extent, LPL (29). HDL 
lipids are mainly catabolized in the liver via SR-BI mediated selective uptake (30) or 
LDL receptor mediated whole particle uptake (31).  
Role of HDL components 
As the smallest (7-12 nm) and most dense (d = 1.063-1.21 g/mL) lipoprotein 
class in plasma, HDL has the highest protein (30-70% by weight) and PL (surface 
molecules, 40-60% of total lipid) content (32). As mentioned above, HDL can exert its 
athero-protective functionality through multiple mechanisms, mainly including RCT, 
anti-oxidation, anti-inflammation, vasodilation and cytoprotection. This broad spectrum 
of HDL functions gives an excellent reflection of the complexity of HDL composition. 
Recent development of mass spectrometry technology has provided novel insight into 
HDL proteome and lipidome. Currently over 80 proteins and more than 200 distinct lipid 
classes have been identified in HDL, many of which have been shown linked to HDL 
functionality and reflective of ASCVD risk (7, 33). 
ApoA-I 
ApoA-I, a 28 kDa protein, is the principal protein of HDL, constituting about 
70% of their protein content (31). ApoA-I has a highly dynamic structure, containing 8 
 5 
 
amphipathic α-helical domains of 22 amino acids each. These helical structures form a 
hinge domain that allows ApoA-I to switch between different conformations and bind 
variable amounts of lipids (34, 35). ApoA-I plays a key role in HDL anti-atherogenic 
function, and is an independent and inverse predictor of CVD (36). ApoA-I can interact 
with ABCA1, ABCG1 and SR-BI and facilitate RCT by promoting cellular cholesterol 
efflux, activating LCAT, and forming mature HDL (37). ApoA-I prevents LDL 
oxidation by removal of seeding phospholipid hydroperoxides from LDL, followed by 
reduction of hydroperoxides using methionine residues as the reductant (38, 39). ApoA-I 
also stabilizes other HDL anti-oxidant enzymes such as PON1 (40). ApoA-I and ApoA-I 
containing reconstituted HDL (rHDL) infusion studies have showed that ApoA-I can 
inhibit endothelial expression of vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1), and effectively reduces monocyte 
activation and neutrophil adhesion (41, 42). A study with transgenic mice showed that 
human ApoA-I diminishes LPS-induced systemic inflammation by suppression of 
cytokine release and reduction of CD14 expression (43). Moreover, ApoA-I has been 
identified as the main HDL component that protects endothelial cells from primary 
apoptosis under oxidative stress (44).  
ApoA-II 
ApoA-II is the second major protein in HDL, constituting about 20% of HDL 
total protein. ApoA-II is synthesized by the liver and mainly found in HDL particles 
containing both ApoA-I and ApoA-II. Unlike ApoA-I, the role of ApoA-II in 
atherogensis and HDL metabolism has not been definitely established. While ApoA-II is 
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an efficient acceptor of ABCG1 mediated cholesterol efflux from macrophages (45), 
HDL isolated from ApoA-II transgenic mice stimulates the production of lipid 
hydroperoxides in endothelial cells and promotes monocyte migration into the artery 
wall (46). Overexpression of human ApoA-II in mice can cause ApoA-I and PON1 
displacement from HDL particles and resulted in accelerated atherosclerosis (47). Data 
from clinical and epidemiological studies are similarly inconclusive. Several 
epidemiological studies have reported that low plasma ApoA-II is associated with 
increased risk of CHD, including the large scale (10,592 subjects) Prospective 
Epidemiological Study of Myocardial Infarction Study (48-51).  On the other hand, data 
from the Etude Cas-Témoins de l'Infarctus du Myocarde (ECTIM) study (1,357 subjects) 
have showed that decreased ApoA-II due to genetic polymorphisms were not associated 
with CHD (52).  
ApoE  
ApoE is a key regulator of cholesterol homeostasis in mammals and is readily 
redistributed between ApoB-containing lipoproteins and HDL. While ApoE only 
constitutes about 6% of HDL total protein (53), it is structurally similar to ApoA-I (54) 
and plays critical roles in RCT. For example, lipid poor ApoE promotes cholesterol 
efflux from ABCA1 pathway and facilitates pre-β HDL maturation into α-HDL (55). 
HDL ApoE also can interact with the polar head groups of HDL phospholipids and 
allows easy core expansion after LCAT converts FC to CE (56). Both ABCA1 and 
ABCG1 are highly expressed in macrophages. In CETP deficient individuals, who have 
large HDL particles and impaired ABCA1 mediated cholesterol efflux, their HDL2 has 
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enhanced ability to promote cholesterol efflux from macrophages in an ABCG1-
dependent pathway due to an increase in ApoE content (57). As a potent ligand for LDL-
R, ApoE promotes the hepatic uptake of HDL CE via LDL-R (58). It can also interact 
with SR-BI and promote SR-BI mediated cholesterol efflux and selective lipid uptake by 
the liver (59). In addition, ApoE confers arthero-protective functions beyond its effect on 
cholesterol metabolism. One recent study showed that HDL ApoE induced 
cyclooxygenase-2 (COX2) up-regulation and lipoxygenase (LOX) down-regulation in 
vascular smooth muscle cells contributes to the suppression of extracellular matrix gene 
expression and thus the maintenance of arterial elasticity (60).  
S1P 
S1P is an important signaling molecule that regulates diverse cellular processes 
involved in immune response. S1P is generated by sphingosine kinase mediated 
phosphorylation of sphingosine, the direct precursor generated from the 
ceramide/sphingomyelin metabolic pathway. In plasma, S1P occurs in a concentration of 
200-1,000 nM and is mostly carried by HDL (~65%-80%) (61). In blood, S1P 
predominantly binds to ApoM and to a lesser extent albumin (62). Erythrocytes are the 
main source of circulating S1P but S1P can also be produced by platelets, vascular and 
lymphatic endothelium (63, 64). The higher concentration of S1P in serum than in 
plasma is attributed to S1P release from platelet activation (65). 
Numerous S1P depletion or S1P receptor blocking studies showed that many 
anti-atherogenic functions of HDL are mediated by S1P and the activation of its five G-
protein coupled receptors termed S1P1→5.  Nofer et al. (16) found that HDL-S1P 
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promotes NO production by the eNOS and induces NO-dependent vasodilation in 
explanted arteries and in vivo via S1P3. On the other hand, Wilkerson et al. (66) have 
showed that HDL-S1P promotes endothelial cell barrier function by inducing persistent 
activation of eNOS and increasing the activity of the downstream NO target, soluble 
guanylate cyclase via S1P1. Kimura et al. (67) have demonstrated that HDL-S1P 
modulates endothelial cell proliferation and survival by activating extracellular signal-
regulated kinase (ERK) and that endothelial migration was sensitive to both S1P1 and 
S1P3, while cell survival was exclusively sensitive to S1P1 (68). The same group later 
showed that HDL inhibits the production of MCP-1 in endothelial cells and this process 
is mediated by the coordinate signaling through S1P3 and SR-BI receptors. The 
expression of many adhesion molecules is regulated by ROS-dependent mechanisms. 
HDL-S1P attenuates ROS production by inducing NO production and inhibiting 
NADPH oxidase (69). Tölle M et al. (12) reported a similar HDL-S1P induced MCP-1 
and NADPH oxidase inhibitory effect in VSMCs via S1P3. HDL also induces the 
endothelial expression of long pentraxin 3 (PTX3) (70) and transforming growth factor β 
(TGFβ) (71), both of which are key modulators of immune response. The authors 
attributed these observed effects to the activation of S1P1 and S1P3 by HDL-S1P. 
Interestingly, HDL appears to have carrier-specific effects on S1P signaling. Compared 
with albumin bound S1P, HDL-S1P induces prolonged S1P-S1P1 signaling involving 
persistent activation of Akt and eNOS. HDL as a carrier, reduces the rate of S1P1 protein 
degradation and promotes recycling of internalized S1P1 (66). In addition, HDL receptor 
systems, such as SR-BI, may cooperate with S1P receptor systems in HDL induced 
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signaling (69) and part of the effects may be attributed to the particle docking function of 
HDL receptors on the cell surface (16).  
As the protective role of HDL-S1P has been convincingly illustrated in molecular 
and cellular studies, in recent years, researchers have started to conduct human studies 
and examine the status of HDL-S1P in disease conditions. In two separate studies, HDL-
S1P have been reported to be lower in patients with stable coronary artery disease 
(CAD) than in healthy controls and that HDL-S1P is inversely associated with the 
occurrence of coronary artery disease, independent of HDL-C concentration (72, 73). 
Further research has showed that HDL-S1P is inversely associated with the severity of 
CAD and is an independent predictor for coronary in-stent restenosis (74, 75). 
Oxylipins 
Oxylipins are a structurally and functionally diverse array of lipid mediators 
derived from polyunsaturated fatty acids (PUFA). Over the last decade, oxylipins have 
emerged as important regulators of inflammatory progress and have been implicated in 
various inflammatory conditions including type 2 diabetes, cardiac surgery, proteinuric 
hyperlipidemia and Immunoglobulin A nephropathy (76-79). They can be generated 
either via auto-oxidation by ROS or via the actions of three enzyme families including 
COX, LOX, and cytochrome P450 (CYP)(80). PUFAs are susceptible to auto-oxidation 
and the main products include hydroperoxides, hydroxyl-FA and prostanoids (81). The 
COX pathway leads to the generation of the pro-inflammatory prostaglandin H2 
(PGH2), PGF2a, thromboxane A2 (TXA2) and TXB2 as well as the anti-inflammatory 
prostaglandin E2 (PGE2), PGD2, and prostacyclin (PGI2). The LOX pathway contains 
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three types of enzymes 5-LOX, 12-LOX and 15-LOX. The 5-LOX pathway generates a 
series of pro-inflammatory lipid mediators from arachidonic acid (AA) including 5-
hydroxyeicosatetraenoic acids (5-HETE), 5-keto-eicosatetraenoic acid (5-KETE) and 
leukotriene B4 (LTB4) that promote leucocyte chemotaxis (82). n-3 PUFA compete with 
AA for 5-LOX pathway to form less potent metabolites and contributes to the reduction 
of inflammation (83). On the other hand, the products of 12-/15-LOX pathway can have 
dual pro-inflammatory and pro-resolution activities (84). The CYP pathway contains two 
types of enzymes: CYP hydroxylase and CYP epoxygenase, which give rise to alcohol 
and epoxide metabolites respectively. Epoxides contribute to the maintenance of 
vascular homeostasis by promoting vasodilation and angiogenesis and suppressing 
inflammation (85). Epoxides can be further metabolized by soluble epoxide hydrolase 
(sEH), yielding diols. Degradation of epoxides causes them to lose their athero-
protective efficacy. Cellular oxylipins are mainly attached to phospholipids on cell 
membranes and their enzymatic generation depends on cell type (86). Also, the 
metabolites of the different pathways may not be unique to that specific pathway. For 
instance, the 15-LOX product of AA 15-HETE can also be generated from COX and 
CYP pathways as well as by auto-oxidation (87-89).  
The best-characterized oxylipins are AA derived prostanoids including 
prostaglandins and thromboxanes via the COX pathway; they are not known to become 
esterified into phospholipids. In contrast, CYP and LOX derived metabolites can become 
incorporated into cellular phospholipids as well as neutral triglycerides and cholesterol 
esters. Over 90% of circulating oxylipins occur as esterified forms in lipoproteins (90) 
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and they are differentially distributed among different lipoprotein compartments. For 
example, 13-hydroxyocta-decadienoate (13-HODE), the linoleic acid (LA) derived 
alcohol product, which has been reported to promote macrophage accumulation in 
plaques (91), is most enriched in HDL. In fact, HDL particles contain the highest load of 
alcohols, epoxides and total oxylipins (90). So far, little is known about the sources for 
lipoprotein oxylipins and how they are metabolized. But HDL particles are relatively 
small and can readily enter extracellular spaces. HDL also lacks heparin binding site and 
thus is normally not retained in extracellular matrices. The unique physiochemical 
property of HDL particles makes them an ideal shuttle platform for lipid transportation. 
This property may account for their distinctive oxylipin profile. As enzymatically 
derived oxylipins are exclusively generated inside cells and incorporated into cell 
surface, it is possible that HDL acquires the oxylipins from peripheral cells and immune 
cells such as macrophages and neutrophils as well as other lipoprotein particles in the 
same manner they acquire triglycerides and phospholipids. It is also unclear whether 
HDL oxylipins are mainly targeted for hepatic disposal or if they function in an 
endocrine manner. It has been demonstrated that esterified oxylipins in VLDL can be 
liberated by lipoprotein lipase and act as lipid mediators (78). Alternatively, 5-LOX 
derived oxylipins esterified in phospholipids can modulate immune response in 
neutrophils and it would be interesting to know whether HDL oxylipins directly interact 
with cell surface oxylipin receptors and whether HDL receptors such as SR-B1 and 
ABCA1 participate in a co-ordinated signaling with oxylipin receptors.  
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With the improvement in the accuracy, sensitivity and speed of liquid 
chromatography and mass spectrometry as well as the development of bioinformatics 
(77, 92), oxylipin profiles can now be generated rapidly and be used to discriminate 
disease phenotypes. A handful of studies demonstrated the alteration in circulating 
oxylipin profile during inflammation and oxidative stress, both of which are well-
defined atherothclerosis risk factors. In type 2 diabetes patients, plasma epoxides and 
ketones of 18 carbon PUFA were increased by over 80% and were positively associated 
with changes in plasma non-esterified fatty acids (NEFA) (93). During cardiac surgery, 
the activity of LOX pathway was up-regulated and elevated concentrations of the 
chemoattractants 5-HETE and 12-HETE were observed (77). As circulating oxylipins 
are differentially distributed, it remains to investigate how oxylipin profiles of different 
lipoprotein subclasses compare to total plasma oxylipin profile in disease risks 
prediction. 
HDL remodeling and functionally defective HDL 
While HDLs are generally perceived as athero-protective particles and HDL-C 
has been identified as an independent predictor for ASCVD, a significant number of 
coronary heart disease (CHD) events occur in individuals with normal HDL-C. Indeed, 
in the original Framingham study, over 40% (44% for men and 43% for women) of the 
CHD events occur in men with HDL-C ≥40 mg/dL and women with HDL-C ≥50 mg/dL 
(94). Consequently, continuing efforts have been made in study of HDL functions and in 
search of markers with better predictive value on the individual level. The concept of 
dysfunctional HDL was first developed about 20 years ago when Fogelman and 
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colleagues (95) found that the normally anti-inflammatory HDL was converted to a pro-
inflammatory particle during an acute phase response in both humans and a croton oil 
rabbit model. They constructed an “inflammatory index” for HDL, as defined by the 
relative capacity of HDL to inhibit monocyte chemotaxis induced by oxidized LDL. In a 
seminal study, this group demonstrated that HDL from patients with CHD who had 
normal concentrations of HDL-C, had reduced anti-inflammatory activity when 
compared with healthy controls (96). In fact, the HDL from many CHD patients had 
increased monocyte chemotaxis in response to oxidized LDL. A number of other studies 
further showed that HDL can also display a complete loss of vasodilatory (97, 98) and 
antiapoptotic function (99), as well as a partial loss of antioxidative (100, 101) and 
cholesterol efflux function (102-104). Chronic inflammation is characterized by 
increased oxidative stress and overproduction of inflammatory protein by the liver and 
macrophage, which triggers pronounced protein and lipid remodeling of HDL with the 
subsequent disruption of HDL athero-protective functions.  
Oxidative change 
In response to pro-inflammatory cytokines and growth factors, several 
phospholipases, in particular cytosolic phospholipaseA2 (cPLA2), are activated and 
release PUFA from cell membranes (105). Free PUFA can undergo peroxidation via 
enzymatic and non-enzymatic pathways and forms the intermediate hydroperoxides, 
which lead to the generation of the alcohol and ketone products. Excess generation of 
ROS and activation of LOX enzymes during inflammation contribute to enhanced 
production of oxidized lipids. In fact, 5-LOX and cPLA2 share the same structural (C2 
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domain) and regulatory (activation by Ca2+ and by phosphorylation) properties and are 
often co-regulated (106). In chronic inflammatory mice models, HDL oxylipin profiles 
were shown to possess increased 5-HETE and 9-HETE, which are biomarkers for 5-
LOX activation and auto-oxidation respectively (78). Human studies have shown that 
HDL from patients with diabetes and CVD are more enriched with LA (9-HODE, 13-
HODE) and AA (5-HETE, 12-HETE, 15-HETE) derived alcohol oxylipins compared 
with healthy controls (107, 108), despite a similar CVD risk factor profile (similar age, 
high blood pressure, lipid profile, and overweight). The authors speculated that the 
accumulation of oxidized lipids play a role in the observed PON1 inactivation and HDL 
dysfunction. In addition to lipids, HDL proteins can also be oxidized during 
inflammation. Myeloperoxidase (109) and 15-LOX (110) are two oxidative enzymes 
capable of ApoA-I modification and have been implicated in human atherosclerotic 
lesions. Leukocyte released myeloperoxidase mediates carbamylation of lysine residues 
and oxidation of methionine and tryptophan residues on ApoA-I and thereby diminishes 
ABCA1 dependent cholesterol efflux and LCAT activity (111-116) as well as eNOS 
expression and activity (117). 15-LOX can induce ApoA-I and ApoA-II cross-linking 
and thereby decreases SR-BI dependent cholesterol efflux from macrophages (118).  
Protein/lipid distribution change 
Serum amyloid A (SAA) is a family of apolipoproteins overproduced during 
acute phase response that are capable of displacing ApoA-I in HDL (119). HDL 
proteomics analysis showed that ApoE preferentially resides in the large HDL2 
subfraction. A shift in the distribution of the majority of ApoE towards smaller HDL 
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particles has been reported in CAD and diabetic patients (33, 120). It has been 
hypothesized a shift of ApoE from HDL2 to HDL3 may impair ApoE mediated 
cholesterol efflux from macrophages. HDL-S1P has been found to be lower, whereas 
non-HDL-S1P were higher in patients with myocardial infarction and CAD, when 
compared with healthy individuals, suggesting that the health status of an individual may 
affect the partitioning of S1P to HDL (72-74). As mentioned above, HDL has carrier 
specific effects on S1P bioactivity and the shift of S1P towards other lipoproteins or 
albumin may impair HDL functionality. In support of this assumption, Sattler et al. (72) 
reported that the concentration of HDL-S1P is negatively associated with the severity of 
CAD symptoms, whereas that of non-HDL-S1P increases proportionally with the 
severity of CAD. The same group recently demonstrated that the reduction of HDL-S1P 
in CAD patients translates to impaired HDL signaling. The reduction is possibly caused 
by oxidative modification of HDL constituents such as ApoM. S1P enrichment in CAD-
HDL by pharmacological blockade of S1P lyase or by administration of S1P-loaded 
erythrocytes corrects HDL dysfunction. It should be noted that HDL is highly 
heterogenous in composition. HDL3 is preferentially enriched in the anti-oxidant enzyme 
PONase and PAFAH (120), the anti-inflammatory phospholipid S1P and its carrier 
ApoM (121), as well as pro-inflammatory proteins such as SAA1 and SAA2 (120). 
While the HDL3 subclass has higher arthero-protective capability under normal 
conditions (44), it is also more susceptible to compositional change and function loss 
during inflammation.  
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Density distribution change 
HDL proteins and lipids play key roles in HDL metabolism, thus a change in 
composition is often associated with altered metabolism. ApoA-I oxidation and 
displacement impairs ABCA-I dependent cholesterol efflux. In the presence of 
myeloperoxidase metabolites such as hypochlorous acid (HOCl) or hydrogen peroxide, 
HDL3 become unable to activate LCAT (116). Secretory phospholipaseA2 (sPLA2), a 
potent inflammatory reactant, can hydrolyze HDL phospholipids, reducing surface 
fluidity of the particle, and therefore impair SR-BI and ABCG1 dependent cholesterol 
efflux (25, 122). Further, cholesterol transporters including ABCA1, ABCG1 and SR-BI 
have all been reported to be down-regulated during inflammation (123, 124). The 
diminished RCT capacity prevents small HDL from maturation and often cause a shift in 
HDL density distribution. Indeed, small spherical HDL phenotype has been reported to 
be associated with increased risk for CHD and acute ischemic stroke independent of 
HDL-C (125-127). CVD patients with normal HDL-C may result from decreased HDL-
C turnover through hepatic uptake and utilization instead of fully functional RCT. Other 
inflammatory disorders such as metabolic syndrome, type 2 diabetes and obesity are also 
characterized by the disappearance of large buoyant HDL and the prevalence of small 
dense HDL (128-130), though the increased small dense HDL may be partially attributed 
to the intravascular lipolysis of triglyceride-enriched HDL. 
To sum up, the process of HDL-C metabolism is complex and the functionality 
of HDL is largely dependent on its composition, which can alter in a variety of disease 
states. Steady-state levels of HDL-C provides little information on the actual rate of 
 17 
 
cholesterol efflux, nor on HDL’s anti-inflammatory, anti-oxidant and endothelial 
protecting activities. Therefore, it has been proposed that HDL subclass distribution and 
composition may be better determinant of HDL mediated athero-protection and their 
measurement may be superior to HDL-C in predicting cardiovascular disease (33, 131, 
132).  
Tools for HDL subclass measurement 
HDL is a heterogeneous mixture of particles, which are composed of a 
hydrophobic lipid core and an outer shell of amphipathic lipids and proteins with distinct 
chemical and physical properties. Based on density, size, surface charge, lipid methyl 
groups and protein composition, lipoprotein subclasses can be measured by various 
analytic methods including ultracentrifugation, gel electrophoresis, precipitation-based 
methods, nuclear magnetic resonance (NMR) spectroscopy, ion mobility etc. The use of 
different techniques and procedures has led to different terms in defining HDL species. 
Ultracentrifugation is a classic method used for HDL separation and subclass 
identification on the basis of hydrated density. Sequential ultracentrifugation divides 
spherical HDL particles into two main subclasses: large, light, lipid rich HDL2 (d = 
1.063-1.125 g/mL) and small, dense, protein rich HDL3 (d = 1.125-1.21 g/mL). With 
density gradient ultracentrifugation, HDL can be further divided into 5 subclasses in 
order of decreasing diameter and increasing density, HDL2b (d = 1.063-1.091 g/mL), 
HDL2a (d = 1.091-1.110 g/mL), HDL3a (d = 1.110-1.133 g/mL), HDL3b (d = 1.133-1.156 
g/mL) and HDL3c (d = 1.156-1.179 g/mL). The density intervals of the 5 subclasses are 
defined to match up with the 5 subclasses that are identified using polyacrylamide 
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gradient gel electrophoresis: HDL2b (9.7-12.9 nm), HDL2a (8.8-9.7 nm), HDL3a (8.2-8.8 
nm), HDL3b (7.8-8.2 nm), HDL3c (7.2-7.8 nm). 
The earliest HDL isolation method is analytical ultracentrifugation, which was 
developed over 70 years ago. HDL subclasses are separated by flotation rate in a salt 
solution (neutral salts, such as NaBr or KBr) of density 1.2 g/mL and their total mass are 
quantified by Schlieren optics. Three HDL subclasses, i.e., HDL1, HDL2 and HDL3, can 
be separated. HDL1, the subclass with the highest flotation rate, is generally not 
detectable in human plasma (133). In the early 1980s, an isopycnic, density gradient 
ultracentrifugation approach was developed by Chapman et al. (134) which can separate 
HDL into 5 subclasses (HDL2b, HDL2a, HDL3a, HDL3b, HDL3c) in a single spin. This 
method requires 3 mL plasma or serum and blood samples are centrifuged in a swing-out 
rotor at 40k rpm (288,000g at rmax) for 48 h. The density gradient is constructed by 
consecutive layering of 4 NaCl-KBr solutions of distinct densities at centrifugation 
temperature. Vertical auto profile (VAP) is another single spin, density gradient based 
ultracentrifugation technique (135). With the use of a vertical rotor (80k rpm, 509,644g 
at rmax) and two pre-formed density gradient layers (NaCl and NaCl-KBr), all 
lipoproteins can be separated in less than 1 h. Following ultracentrifugation, VAP 
measures cholesterol content in two major HDL subclass, HDL2 and HDL3, by a 
controlled-dispersion flow analyzer. This method is sensitive, requiring only 50 µL 
plasma or serum. However, as lipoproteins are resolved along the long axis of the tube 
during ultracentrifugation, they will reorient to the horizontal axis upon completion of 
ultracentrifugation. The high degree of reorientation may result in contamination of 
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lipoprotein classes. Analytic and preparative ultracentrifugation are gold standards for 
lipoprotein subclass separation as they are precise and reproducible (136). However, 
these ultracentrifugation methods have a few common limitations. Exposure to high 
ionic strength and high centrifugal force can result in apolipoprotein loss in HDL 
particles (137). Moreover, they are either labor intensive (manually prepare pre-formed 
density gradient) or time consuming. 
More recently, a novel and rapid method for lipoprotein density profiling has 
been reported using the combination of metal ion EDTA density gradient 
ultracentrifugation, fluorescent staining of lipoproteins and digital imaging (138, 139). 
Pre-stained lipoproteins are separated by metal ion EDTA density gradient 
ultracentrifugation and quantified by measuring the distribution of fluorescent dye. With 
the use of a high speed, fixed angle rotor (120k rpm, 627,000g at rmax), a lipoprotein 
density profile can be achieved within 6 h. Metal ion EDTA salts as density gradient 
medium have the advantage of high molecular weight, small partial volume, and low 
viscosity, allowing rapid formation of a gradient from a homogeneous solution as well as 
reduced ionic strength and accumulated centrifugal force. The elimination of the need 
for step gradients and adjustments for density solution by salt addition also provides 
greater reproducibility than conventional ultracentrifugation methods. Further, 
fluorescence imaging is a highly sensitive quantification method, requiring only 6 µL 
plasma or serum for a high resolution profile. As lipoprotein subclass are identified by 
their hydrated density, this approach requires density gradient formation characterization 
for individual rotors to insure accuracy. 
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Dietary fatty acids and ASCVD risk 
The quantity and quality of dietary fats are major regulators of blood lipid profile 
and ASCVD risk. SFA is long known to elevate LDL-C, a primary risk factor for 
ASCVD (140). In addition，SFA can increase ASCVD risk by promoting the 
production of inflammatory cytokines, impairing endothelial function and insulin 
sensitivity (141-143). Reduction in dietary SFA intake (<7% total energy) is 
recommended by the American Heart Association and National Cholesterol Education 
Program for ASCVD prevention and treatment (144, 145). For energy balance purpose, 
the reduction in SFA intake requires its replacement by other macronutrients. The 
beneficial effects of high MUFA diets initially received attention as multivariate analysis 
showed that MUFA enriched Mediterranean diets were associated with decreased 
incidence of CHD (146). Compared with a high SFA average American diet (34% fat; 
16% SFA, 11% MUFA) diet, high MUFA diets (34% fat; 7% SFA, 18-21% MUFA) 
lowers LDL-C by similar magnitude as a high carbohydrate, low fat NCEP Step II diet 
(25% fat; 7% SFA, 12% MUFA) in healthy normocholesterolemic individuals. 
However, such diets did not elevate TAG or decrease HDL-C concentration, as did a 
high carbohydrate, low fat diet  (147). Meta-analysis of 60 controlled trials showed that 
when carbohydrates constituting 1% of dietary energy were replaced isoenergetically 
with MUFA, total-C:HDL-C and ApoB were reduced. No such change was observed 
when carbohydrate was substituted by SFA (148). In subjects at risk of metabolic 
syndrome, a high SFA diet (19% SFA, 11% MUFA) has been reported to up-regulate the 
expression of inflammatory genes in adipose tissue, while a high MUFA olive oil diet 
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(11% SFA, 20% MUFA) promoted the expression of anti-inflammatory genes (149). 
Further, isoenergetic substitution of SFA by MUFA have been shown to decrease 
diastolic blood pressure, improve flow-mediated dilation (endothelial function 
assessment) and decrease concentration of the cell adhension molecule P-selectin in 
healthy subjects, all of which changes were associated with reduced ASCVD risk (142, 
150). 
Beef consumption and ASCVD risk 
Beef is the most commonly consumed red meat in the US. The U.S. Department 
of Agriculture’s (USDA) 1994-1996 Continuing Survey of Food Intakes by Individuals 
(CSFII) showed that approximately 75% of the population including adults and children 
consumed beef during a 2-day period (151). Beef is a naturally nutrient-rich food 
providing high amounts of protein, vitamin B6 and minerals such as iron and zinc (152). 
Beef is also a major contributor to MUFA intake in US (153, 154). Oleic acid is the most 
abundant MUFA in beef and is converted from stearic acid by Δ9 desaturase (155). The 
fatty acid profile of beef can be modulated by altering the diets of cattle. It has been 
reported that activity of stearoyl-CoA desaturase (SCD) gene, which encodes Δ9 
desaturase, is higher in corn-fed steers than pasture-fed steers (156) and contributes to 
the higher MUFA content in corn-fed beef (157, 158). Beef consumption pattern 
analysis indicates that ground beef held the highest market share with about 42% (159), 
and over 65% of the ground beef consumed in the US contains 16-30% fat. In retail 
outlets, ground beef MUFA:SFA ratio varies widely and can range from 0.84 to 1.46 
(160).  
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While some epidemiological studies reported adverse health associations for red 
meat, this may be attributed to the high SFA intake (161). As MUFA has been suggested 
to be more beneficial than SFA and that MUFA:SFA has a wide range in beef, the effect 
of beef fatty acid composition on ASCVD risk factors has been evaluated by several 
studies. In a dietary intervention study, 10 mildly hyper-cholesterolemic free-living men 
consumed two types of ground beef patties (114 g, 35%wt fat) of differing MUFA:SFA 
ratios for 5 wk with a 3 wk washout period between the diets (160). During the feeding 
periods, the participants were first on a low MUFA (M:S = 0.95, pasture-fed) beef diet 
and then rotated to a high MUFA (M:S = 1.31, corn-fed) beef diet. Results showed that 
the low MUFA beef diet increased plasma concentration of TAG and reduced 
concentration of HDL-C. And these adverse effects on lipid profile were abrogated after 
consumption of the high MUFA:SFA beef diet, indicating the high MUFA beef either 
reversed the negative effects of the low MUFA beef diet or at least was neutral in its 
effects on plasma lipids. In a subsequent study, the health effects of beef fatty acid 
composition were evaluated in 27 healthy free-living men in a random crossover design 
(162). The two beef patties designed for the study were 114 g, 24%wt total fat, with a 
M:S = 0.71 for low MUFA beef and a M:S = 1.1 for high MUFA beef. The participants 
completed two 5 wk feeding trials in which 5 patties were consumed per week and the 
initial assignment to low or high MUFA beef was random. Results showed that HDL-C 
had a trend to increase with the consumption of both beef diets. However, the elevation 
was only significant for the high MUFA beef diet. It remains unknown whether the 
increase in HDL-C translates to an increase in functional HDL particles.  
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On the other hand, the SFA intake recommended by the American Heart 
Association was <7% of energy. Dietary Approaches to Stop Hypertension (DASH) is a 
gold standard heart healthy diet which features more fruit and vegetable as well as less 
SFA, cholesterol and red meat intake (163, 164). To test whether lean beef could be 
included in an athero-protective diet, the Beef in an Optimal Lean Diet (BOLD) study 
compared the cholesterol lowering effects of DASH and two different low SFA, lean 
beef enriched DASH-like diets in a mildly hypercholesterolemic population (165). A 
primary outcome was that lean beef as main protein and partial replacement of 
carbohydrates by protein (including lean beef) in DASH-like diet decreased LDL-C, 
HDL-C and total-C by a similar magnitude as DASH diet. It remains unknown the effect 
of beef as a main protein source in a DASH-like diet on lipoprotein density distribution 
and how that may be influenced by total fat intake.  
Present study 
Objectives:  
1. To determine the effects of ground beef fatty acid composition on HDL density   
distribution, HDL oxylipin profile and HDL3 composition in healthy men  
consuming ground beef containing 24% fat of differing degrees of saturation.  
2. To validate the method of lipoprotein density profiling by NaBiEDTA density 
gradient ultracentrifugation using a fixed angle MLA-130 rotor and apply the method 
to HDL density distribution analysis. 
3. To compare the effects of beef consumption on HDL density profiles in two separate 
populations with differing total fat intakes as an add-on study.  
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CHAPTER II 
GROUND BEEF ACID COMPOSITION INFLUENCES HDL3 SPHINGOSINE-1-
PHOSPHATE CONTENT AND IS RELATED TO ATHEROSCLEROTIC 
 CARDIOVASCULAR DISEASE RISK FACTORS IN HEALTHY MEN 
 
Introduction 
Dyslipidemia, glucose intolerance and oxidative stress are strongly associated 
with increased ASCVD risk (2). Low HDL-C is a common dyslipidemia identified by 
the National Cholesterol Education Program Adult Treatment Panel III as an 
independent risk factor for ASCVD (2, 166). However, large clinical trials to increase 
HDL-C through pharmacologic agents show no clear ASCVD risk reduction with 
increases in HDL-C concentration (166). HDL particles are highly heterogeneous in 
physiochemical and biological properties (166). Accumulating evidence suggests that 
small HDL3 particles can lose their functionality for RCT, anti-inflammation and anti-
oxidant activity or even become atherogenic under inflammatory states due to 
compositional changes in lipid and protein components (131, 167). Furthermore, 
ASCVD patients with higher concentrations of HDL3 in the presence of increased larger 
VLDL were demonstrated to be 3-4 times more likely to develop extensive coronary 
artery disease (168). In diabetic patients, amounts of HDL3 tend to comprise a greater 
proportion of total HDL mass independent of serum triglycerides (TG) and total HDL-C 
(169).  
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Increases in HDL-C with higher intakes of SFA and MUFA is well documented 
(170). However, whether such dietary induced increases result in increased amounts of 
functional HDL is not known. In our previous study, subjects consuming 5, 114g 
ground-beef patties (27 g fat/114g patty of either high (1.10) or low (0.71) MUFA:SFA) 
per week for 5 wk exhibited increased HDL-C, with a greater (P <0.05) increase 
observed following high MUFA ground beef consumption (162). Average diameters of 
HDL2 and HDL3 were similar across groups but the proportion of HDL in each diameter 
subfraction was not determined. This determination was of interest as the small and 
dense HDL3 subclass is believed to include both the most beneficial and the most 
detrimental species of HDL (171, 172). Thus changes in the amount of this HDL 
subclass can have different biological actions. Ambiguity in risk/benefit assignments for 
HDL subclasses currently limits the diagnostic value of traditional measures such as 
total HDL-C. 
In the present study, the effects of ground beef consumption on HDL density 
distribution, HDL3 apolipoprotein composition and S1P content were measured. We also 
examined whether the fatty acid composition of ground beef influenced its effects on 
HDL properties as well as metabolic indices of insulin sensitivity, oxidative stress 
markers and adipokines.  
Methods 
Subjects and design 
Complete sets of banked plasma and serum samples were analyzed from 25 
healthy men (Table 2.1) who successfully completed a beef feeding trial (162). Briefly, 
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participants consumed ground beef with a total fat content of 24%, but in which the 
MUFA:SFA was either high (1.10:1) or low (0.71:1). All subjects consumed both types 
of ground beef, with random initial assignment to the low MUFA or high MUFA 
treatment. All subjects were free-living, but were instructed to replace dietary protein of 
one meal per day with one 114 g ground beef patty for 5 d/wk. Each dietary phase lasted 
5 wk and was followed by a 4 wk wash out period prior to starting the next dietary 
phase. Blood samples were collected following a 14 h fast at the start and end of each 
feeding period. Separated plasma and serum samples were stored at -80 °C prior to 
analysis.  
 
Table 2.1 Baseline characteristics of Patty Study subjects 
Variables    
Age (y) 35.4 ± 2.2 
BMI 27.1 ± 0.8 
TG (mg/dL) 105.0 ± 8.8 
TC (mg/dL) 187.0 ± 7.3 
LDL-C (mg/dL) 120.8 ± 6.6 
HDL-C (mg/dL) 45.6 ± 1.7 
Data expressed as mean ± SEM. n = 25. 
 
Laboratory measurement 
Serum glucose was measured using an enzymatic assay kit (Cat. #GAHK20, 
Sigma-Aldrich, St. Louis, MO) and the activity of PON1 was measured by using freshly 
prepared phenylacetate (Sigma-Aldrich, St. Louis, MO) as substrate and determined by 
spectrophotometric assay (173). Serum insulin was assayed using an ELISA kit (Cat. 
#EZHI-14K, Millipore, Billerica, MA). Homeostatic model assessment (HOMA) score 
was calculated from serum glucose and insulin concentration using a HOMA2 calculator 
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(174) as an estimate of insulin sensitivity. HDL3 (d = 1.125-1.21 kg/L) was isolated from 
plasma by NaCl-NaBr sequential flotation ultracentrifugation and dialyzed against 0.9% 
saline overnight (175). Serum adiponectin, resistin and plasminogen activator inhibitor 1 
(PAI-1) and HDL3 ApoA-I, ApoA-II and ApoE were measured by multiplex 
immunoassay kits (Cat. #HADK1-61K-A and Cat. #APO-62K, Millipore, Billerica, 
MA) using a Luminex analyer (Luminex, Austin, TX).  
Serum homocysteine (S-Hcy) and HDL3 S1P were analyzed by HPLC as 
previously described with modifications (16, 176). Plasma HDL3 S1P was measured 
since over half of the plasma S1P is carried by HDL and most concentrated in the HDL3 
subfractions (121, 177). Protein bound homocysteine was converted to the free thiol 
form by incubation with 100 μL of 1% 2-mercaptoethanol (β-ME) in 40 mmol/L sodium 
borate solution, pH 9.5 at 37 ºC for 30 min. The remaining protein was acid precipitated 
using 100 μL of 1.5 mol/L HClO4, and then neutralized with 50 μL of 2 mol/L K2CO3 
prior to addition of 200 μL 30% (w/v) Brij® 35 solution and 50 μL of an iodoacetic acid 
solution (52 mg iodoacetate, 5 mL 40 mmol/L sodium borate, pH = 9.5). After 
derivatization with 200 μL ortho-phthalaldehyde (OPA) solution (25 mg OPA, 625 μL 
methanol, 25 μL β-ME, 6.25 mL 0.04 mol/L sodium borate, pH = 9.5), homocysteine 
was measured using a Dionex P580 HPLC system (Dionex, Sunnyvale, CA) equipped 
with a 5 μm, 150 × 4.6 mm SUPELCOSIL™ LC-18 column (Sigma-Aldrich, St. Louis 
MO) and Dionex RF2000 fluorescent detector (Dionex, Sunnyvale, CA) set at 340 nm 
excitation and 450 nm emission wavelengths. The mobile phase was 86:14 solution A 
(0.02 mol/L NaAc, 2.68 mmol/L triethanolamine, 0.4%v tetrahydrofuran, pH = 7.2): 
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solution B (10 mmol/L NaAc/methanol/methyl cyanide 5:1:1 v/v/v, pH = 7.2) at 0.8 
mL/min. Concentration of S1P in HDL3 were measured following addition of 20 μL of 
80 ng C17-S1P /mL internal standard to 100 μL of isolated HDL3. Selective extraction 
of S1P was accomplished by liquid/liquid extraction with 1 mL methanol containing 2.5 
μL concentrated HCl, 1 mL chloroform, 200 μL 4 mol/L NaCl and 100 μL 3 mol/L 
NaOH. The alkaline aqueous phase was then transferred to a clean tube and the organic 
phase was re-extracted with 0.5 mL methanol, 0.5 mL 1 mol/L NaCl and 50 μL 3 mol/L 
NaOH. The aqueous phases were combined, acidified with 100 μL concentrated HCl and 
extracted twice with 1 mL chloroform. The S1P-containing chloroform was dried at 
50ºC under nitrogen. For HPLC analysis, S1P was redissolved in 100 μL mobile phase 
(methanol, 70 mmol/L K2HPO4, 78:22 v/v) and combined with 100 μL OPA solution (25 
mg OPA, 625 μL methanol, 25 μL β-ME, 6.25 mL 40 mmol/L sodium borate, pH = 
10.5). The OPA derivatives of S1P were analyzed at a flow rate of 0.25 mL/min using a 
5 μm, 150 x 2.1 mm Kromasil C18 column (Sigma-Aldrich, St. Louis MO) and detected 
by a Dionex RF2000 detector (Dionex, Sunnyvale, CA) using an excitation wavelength 
of 340 nm and an emission wavelength of 456 nm. A calibration curve was generated 
using serial dilutions of S1P standards. S1P was quantified by comparison of its 
fluorescent intensity with that of the internal standards. 
Density profiles for circulating lipoproteins were determined by imaging 6 μL 
serum following 6-((N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)amino)hexanoyl) 
sphingosine (NBD-C6-ceramide) labeling of lipoproteins exactly as described except for 
a change in the respective filters (Semrock, Rochester, NY), namely 465 nm/60 nm 
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bandwidth, part #FF01-460-60-25 for excitation and >500 nm/long pass, part # BLP01-
488R-25 for emission (178). Overall lipoprotein density profile was analyzed as absolute 
area under the curve where image area was measured as pixels (AUC, i.e. number of 
pixels within a density interval) and data were also used to express HDL subfractions as 
percentages of total HDL AUC. The average percent relative standard deviations 
(%RSD) in AUC for different lipoprotein subfractions were 4.45% (within-day) and 
7.37% (day-to-day). To test the effects of sample storage on density distributions, serum 
samples from six non-study subjects were divided into multiple aliquots in order to 
evaluate differences in density distributions of never frozen samples to those of samples 
that had been thawed once, twice, or three times. To test the protein binding properties 
of NBD-C6-ceramide, 6 µL 50 g bovine serum albumin (BSA)/L saline and 
apolipoprotein calibrator containing 660 mg ApoA-I, 290 mg ApoA-II and 360 mg 
ApoE/L were used (Millipore, Billerica, MA). The protein solutions were prepared and 
analyzed by the same methods as serum samples.  
Statistics 
Data analysis was performed using JMP 10.0 (SAS Institute Inc, Cary, NC). The 
distributions of variables were assessed by Shapiro-Wilk test and log transformations of 
skewed variables were used in subsequent analyses. The effect of beef consumption on 
ASCVD risk factors was analyzed by paired t-tests against relevant baseline values. 
Baseline values were averaged for tabular presentation. Simple correlations were tested 
by Pearson's correlation coefficient. Cook’s D distance was calculated and the cutoff 
point for outliers was 4/n. A one-way analysis of covariance was used to adjust lipid 
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confounders for the correlation between HOMA-IR and HDL density distribution. Data 
were expressed as mean ± SEM. The level of significance was P <0.05. 
 
Table 2.2 Effect of low or high MUFA beef intervention on serum ASCVD risk factors, 
HDL density distribution and HDL3 composition 
Variable      Baseline   Low MUFA     High MUFA 
Serum ASCVD risk factors   
HOMA-IR   0.84 ± 0.11a      0.69 ± 0.12b       0.66 ± 0.12b 
S-Hcy (µmol/L)     11.6 ± 0.4     12.5 ± 0.6   12.3 ± 0.5 
PON1 (kU/L)     57.3 ± 1.5     54.7 ± 2.3   56.7 ± 2.2 
PAI-1 (µg/L)     18.8 ± 1.2     19.2 ± 1.7   18.6 ± 1.3 
Resistin (µg/L)     31.6 ± 1.9     29.7 ± 2.4   30.2 ± 2.3 
Adiponectin (mg/L)     15.0 ± 1.5     15.1 ± 1.5    14.1 ± 1.3 
Total lipoprotein, pixels   4620 ± 131     4591 ± 136    4599 ± 118 
Total TRL, pixels       330 ± 35       309 ± 43   290 ± 38 
Total LDL, pixels     2109 ± 94     2025 ± 95   2087 ± 110 
Total HDL, pixels     2181 ± 58b     2257 ± 63a   2222 ± 60a,b 
HDL2/HDL3     1.01 ± 0.07     1.11 ± 0.06   1.05 ± 0.06 
HDL density distribution (% of total HDL AUC) 
HDL2b     20.2 ± 0.9     20.7 ± 1.0   20.1 ± 1.0 
HDL2a     20.4 ± 0.5     21.0 ± 0.4   20.5 ± 0.5 
HDL3a     27.4 ± 0.5     27.2 ± 0.5   27.3 ± 0.5 
HDL3b     19.9 ± 0.6      19.2 ± 0.6   19.9 ± 0.6 
HDL3c     12.2 ± 0.4     12.0 ± 0.4   12.2 ± 0.3 
HDL3 composition   
ApoA-I (mg/L)   439.2 ± 19.2    415.2 ± 17.8   436.8 ± 20.9 
ApoA-II (mg/L)     77.6 ± 6.2     78.6 ± 7.1     84.1 ± 10.1 
ApoE (mg/L)     3.22 ± 0.38  3.15 ± 0.37     3.56 ± 0.40 
All data were expressed as mean ± SEM. n = 25. Two baseline values were averaged for 
table. Effect of beef intervention was determined by paired t-test. Values with different 
superscript letters were significantly different pairwise (P <0.05). Lipoprotein density 
distribution images were measured as pixels. Total pixels were set equivalent to total area 
under the curve (AUC).  
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Results 
The baseline characteristics and dietary intake information for test subjects have 
been previously published (162). Briefly, each type of beef patty provided 27 g of fat. 
The low MUFA patty provided 15 g SFA, 11 g MUFA, 1.3 g trans-fat and 0.85 g 16:1-
n7. Each high MUFA patty provided 13.9 g SFA, 14.5 g MUFA, 0.92 g trans-fat and 
0.97 g 16:1-n7. Compared to baseline intakes, 5 wk of either low MUFA or high MUFA 
beef consumption decreased HOMA-IR score similarly, 11.1% (P = 0.03) and 10.1% (P 
= 0.03), respectively (Table 2.2). Here data were expressed as mean of individual 
percentage changes. There was one particular negative responder whose HOMA-IR 
increased 155% and 212% after the two beef diets, the exclusion of this subject would 
make the decrease in HOMA-IR 17.7% and 19.7% for low MUFA and high MUFA diets 
respectively. There was no change from baseline in the activity of PON1, concentrations 
of homocysteine or PAI-1, adiponectin or resistin after either beef intervention (Table 
2.2). 
Lipoprotein density distribution profile stability 
Figure 2.1 shows the lipoprotein density profile for a representative responder. 
HDL3a was the most abundant HDL subfraction, followed by HDL2a, HDL2b and HDL3b, 
with HDL3c being the least abundant subfraction. The distribution of the NBD-ceramide 
stained apolipoprotein standards and BSA solution following NaBiEDTA density 
gradient ultracentrifugation is shown in overlay (Figure 2.2). The apolipoprotein 
standard shows three small, closely spaced, peaks within the d >1.20 kg/L region of the 
density gradient. The BSA solution showed a tall peak in this same region which 
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corresponded to a similarly large peak in the native serum sample, presumably human 
albumin. Our stability study showed that there was no significant difference in total 
HDL AUC or HDL density distribution following as many as three freeze-thaw cycles 
(Table 2.3). 
HDL density distribution and HDL3 composition 
Compared to baseline distributions, low MUFA beef increased total HDL AUC 
by 3.5% (P = 0.03) while no effect was observed for high MUFA beef (Table 2.2). 
Neither beef intervention altered the fractional abundance of the 5 major HDL 
subclasses measured. Similarly, ApoA-I, ApoA-II and ApoE concentrations in HDL3 
were unaffected by beef consumption. However, HDL3-S1P concentration (µg/mg 
ApoA-I) was increased by 15.6% (P = 0.05) by high MUFA beef consumption relative 
to baseline diet concentration (Figure 2.3). A diminished 7.5% increase over baseline 
HDL3-S1P was observed following low MUFA beef consumption (P >0.05). Aggregated 
post-beef HDL3-S1P concentrations were significantly increased over aggregate pre-beef 
values (P <0.03). The concentration of HDL3-S1P in our study had an overall average 
concentration of 151 nmol/L, comparable to earlier reports (179).  
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Figure 2.1 Lipoprotein density profile for one responder at baseline and after two beef 
diets. 
 
 
Figure 2.2 Density profiles generated using healthy man serum, BSA and apolipoprotein 
mixture. 
 
 
 34 
 
Table 2.3 Effect of freeze thaw cycles on lipoprotein subfraction stability 
Cycle  1  2  3 
TRL 96 ± 5 88 ± 8  75 ± 6* 
LDL1   98 ± 15 113 ± 16    154 ± 34 
LDL2 91 ± 5 95 ± 5    103 ± 5 
LDL3 90 ± 3 95 ± 5    104 ± 5 
LDL4 92 ± 6 95 ± 5    103 ± 6 
LDL5 96 ± 4 96 ± 5    102 ± 6 
HDL2b 96 ± 2 96 ± 1 98 ± 4 
HDL2a 96 ± 2 97 ± 1 96 ± 2 
HDL3a    100 ± 3 99 ± 3    100 ± 5 
HDL3b    106 ± 6    109 ± 9    101 ± 6 
HDL3c    101 ± 9    101 ± 4 96 ± 4 
Total LDL 99 ± 9 99 ± 3    102 ± 5 
Total HDL 98 ± 2 98 ± 1 98 ± 3 
HDL subfractions as % of HDL AUC  
HDL2b 98 ± 2 99 ± 1    100 ± 2 
HDL2a 99 ± 1 99 ± 1 98 ± 1 
HDL3a    102 ± 2    101 ± 2    102 ± 3 
HDL3b    108 ± 5    111 ± 9    103 ± 8 
HDL3c 104 ± 10    103 ± 4 99 ± 4 
Lipoprotein subfraction data after 1-3 freeze thaw cycles were calculated as percentages 
of their fresh compartments and expressed as mean ± SEM. n = 6. The effect of freeze 
thaw cycles were determined by paired t-tests. *P <0.05.  
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Figure 2.3 HDL3-S1P before and after beef consumption. n = 25. C17-S1P was used as 
an internal standard during extraction procedure and S1P was calculated using the 
standard curve shown on the top right (y = 1.7095x + 0.012, R2 = 0.9997 where y is the 
concentration of S1P and x is S1P AUC:C17-S1P AUC). HDL3-S1P concentration was 
normalized to ApoA-I content. Effect of beef on S1P was determined by paired t-test.  
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Correlations of HOMA-IR and HDL3-S1P with other ASCVD risk factors 
Simple correlations were calculated for baseline and endpoint HOMA-IR and 
HDL3-S1P and other analytes measured specifically for this study; additional 
correlations were calculated using total-C, TG, HDL-C, LDL-C and high sensitivity C-
reactive protein (hsCRP) measured previously (162) (Table 2.4). HOMA-IR was most 
strongly and positively associated with TG and the fractional abundance of HDL3a and 
HDL3c (P <0.001); and conversely, negatively associated with the fractional abundance 
of HDL2b (P <0.001). The correlations with the largest diameter subclass HDL2b (r = -
0.41, P <0.01) and smallest diameter subclass HDL3c (r = 0.46, P <0.01) remained 
significant after adjustments for total HDL-C and TG. HOMA-IR was also positively 
correlated with hsCRP (P <0.01), resistin (P <0.01) and HDL3b (P <0.05) and negatively 
correlated with HDL-C (P <0.01) and HDL3-S1P (P <0.05). HDL3-S1P was most 
strongly and positively correlated with total HDL-C and negatively with hsCRP, PAI-1 
and resistin (P <0.001). To a lesser extent, S1P was negatively correlated with HDL3c (P 
<0.01) and HDL3 ApoA-I (P <0.05).  
Correlations of beef induced changes in HOMA-IR and HDL3-S1P with baseline ASCVD 
risk factors  
Additional correlations to baseline ASCVD risk variables were calculated for the 
changes in HOMA-IR and HDL3-S1P after beef intervention. Negative correlations were 
observed for the change in HOMA-IR with baseline HDL-C (P <0.05) and the change in 
HDL3-S1P with baseline TG (P <0.001), total-C (P <0.01) and LDL-C (P <0.01) (Figure 
2.4). 
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Table 2.4 Pearson correlation coefficients among HOMA-IR, HDL3-S1P and serum 
ASCVD risk factors, HDL density distribution and HDL3 apolipoprotein 
Variable   HOMA-IR  HDL3-S1P 
Serum ASCVD risk factors   
HOMA-IR         -0.22* 
TG   0.30***   -0.17 
Total-C    0.12   0.22* 
LDL-C    0.14       0.18 
HDL-C   -0.25**       0.28*** 
hsCRP     0.24**     -0.29*** 
S-Hcy     0.09      -0.11 
PAI-1    0.19   -0.35*** 
Adiponectin  -0.12       0.03 
Resistin    0.24**                         -0.37*** 
PON1    -0.15       0.05  
HDL density distribution (% of total HDL AUC) 
HDL2b   -0.44***   0.21* 
HDL2a   -0.19   0.14 
HDL3a    0.36***     -0.16 
HDL3b    0.20*     -0.17 
HDL3c    0.37**     -0.22* 
HDL3 composition    
ApoA-I   -0.07   -0.26** 
ApoA-II   -0.14   -0.10 
ApoE    0.01       0.03 
ApoE/ApoA-I   0.02        0.13 
Values are Pearson correlation coefficients. Outliers were tested by Cook’s D Distance 
and 0-3 outliers were excluded for each correlation test. n = [97, 100] *P <0.05; **P 
<0.01; ***P <0.001.  
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Figure 2.4 Correlations between 5 wk beef intervention induced changes in HOMA-IR 
with baseline HDL-C (A) and changes in HDL3-S1P with baseline TG (B), LDL-C (C) 
and total-C (D).  
 
 
Discussion 
Consumption of either type of ground beef reduced HOMA by ~20% without 
affecting HDL density profile or amounts of ApoA-I, ApoA-II, Apo-E in HDL3, or 
PON1 activity in plasma or markers of systemic inflammation and obesity. However, 
consumption of MUFA rich ground beef significantly increased HDL3-S1P, suggesting 
that this form of beef enhanced HDL functionality. Functional HDL is defined by its 
ability to carry out RCT as well as other atheroprotective actions such as suppression of 
inflammation, thrombosis, apoptosis and oxidation in the vascular wall while promoting 
 39 
 
vasodilation and resistance to infection (166). Effective RCT forms mature HDL2b 
particles and this component of HDL is most often associated with reduced ASCVD risk 
(180).  
The uniform improvement in insulin sensitivity by both beef diets in the present 
study may indicate that the beneficial effects were at least partially due to lean 
components of the meat, and perhaps improved dietary protein quality (165) as total 
dietary protein intake did not change (162). One possible explanation for the lack of a 
more beneficial outcome MUFA rich beef consumption was that by design, the 
MUFA:SFA was chosen to match the range of beef compositions commonly available in 
retail stores (162). Beef is a major contributor to MUFA intake in US (181, 182) and 
beef is most commonly consumed as ground beef (159). Other studies have created 
differences in daily MUFA intake of more than 13 g, much larger than the ~3g increase 
tested here. Moreover, some studies used combinations of dairy fat rather than intrinsic 
beef fat (183) to modify fat intake, and tested MUFA/SFA effects in diet with fat 
contents lower than 37% of energy rather than the 39% of energy used here (184) 
complicating direct comparisons.  
HDL density profile was measured using NBD-ceramide labeled lipoprotein 
particles. Unlike chemical measurement of HDL-C, this method reflects overall particle 
mass density distribution expressed as AUC for density-defined regions. Serum samples 
used in the present study were thawed once. Freeze thaw cycles will alter some lipid 
measurements (185, 186), but 3 freeze-thaw cycles did not affect HDL density 
distribution or total AUC; albeit TRL AUC was significantly reduced. Total HDL AUC 
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was increased by low MUFA beef consumption by ~3.4%, while the 1.8% increase 
observed following high MUFA beef consumption was not significant. Interestingly, 
previous chemical measurement on replicate samples from this same study showed that 
HDL-C was only significantly elevated by MUFA rich beef consumption (162). 
Cholesterol comprises about 15% of HDL mass, and its chemical measurement in 
conjunction with density distribution information might assess HDL functionality in 
regards to RCT if an increase in HDL2b AUC were observed. In this study, neither beef 
intervention caused changes to HDL density distribution. However, correlation analysis 
confirmed that HDL density subclasses were variably associated to ASCVD risk factors 
in a manner consistent with prior studies using beef as a protein source (160, 165, 183) 
as well as earlier prospective studies conducted on HDL subclass distribution and insulin 
sensitivity (169, 187, 188), indicating that the density distribution measurements are able 
to capture known physiological associations. Thus a question develops regarding what 
besides cholesterol contributed to the greater HDL AUC increase seen following low 
MUFA beef consumption. 
Compositional change is a major cause for dysfunction within small and dense 
HDL. One study using shot-gun proteomics found ApoE enrichment in HDL3 from 
cardiovascular patients (172). HDL3 apolipoprotein composition was not influenced by 5 
wk consumption of either beef type, nor did HDL3 ApoE content correlate with HDL3-
S1P, HOMA-IR or other inflammatory markers. Enrichment of HDL with the bioactive 
lipid S1P is thought to confer numerous atheroprotective effects (12, 13, 189). HDL3-
S1P concentration increased after 5 wk of MUFA-rich beef consumption, suggesting an 
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improvement in HDL3 functionality with consumption of this beef type. While only 
weak or non-significant correlations were observed for total HDL3-S1P and plasma TG, 
LDL-C and total-C, the magnitude of increase in HDL3-S1P following ground beef 
consumption was strongly correlated with baseline values of these variables. Low 
baseline values for plasma TG, LDL-C and total-C were associated with the greater 
increases in HDL3-S1P post-beef consumption. The average tabular values may not 
adequately characterize the response of individuals.  
Metabolic inflexibility (190) as indicated by an elevated HOMA-IR value, was 
associated with increased proportions of the smallest and most dense HDL3c subfraction 
and decreases in the large HDL2b particle associated with efficient RCT. Interestingly, 
ApoM is reported to be the sole carrier of S1P, and this apoprotein is found primarily in 
HDL3 (62), however, ApoM is displaced towards TRL during postprandial lipemia and 
in dyslipidemic subjects (191, 192). In the current sample set HDL3-S1P content was 
negatively associated with a fractional increase in the smallest and most dense HDL3c 
subfraction, a subfraction whose increase was in turn associated with increases in 
HOMA-IR, suggesting that S1P did not associate with HDL3 lipoprotein material formed 
in metabolically inflexible individuals; i.e. most likely dysfunctional non-ApoM 
containing HDL. Redistribution of ApoM to TRL may blunt S1P benefit mediated by the 
HDL activated SR-BI receptor as it is reported to co-operate with S1P receptors (12). 
Formation and lipolysis of triacylglycerol-rich HDL or failed RCT-mediated conversion 
of HDL3 into HDL2 due to dyslipidemia and inflammation could increase the abundance 
of HDL3 lacking S1P. We found that HDL3-S1P inversely correlated with the 
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prothrombotic or inflammatory markers of PAI-1 resistin and hsCRP, consistent with 
reported general anti-inflammatory properties of HDL3-S1P (12, 13).  
Limitations of the present study include a small sample size and free-living 
conditions of subjects that could compromise rigor of dietary adherence. Diet records 
(193) indicate subject intakes of folic acid, vitamin B6 and vitamin B12, that averaged 
84%, 107% and 100% of the RDA for men 18-70 years old (194). These intakes are 
consistent with unchanged concentrations of the putative oxidative stressor 
homocysteine despite beef being a rich source of its parent molecule methionine. Less 
well-nourished individuals might differ in their response to beef intake. We did not 
conduct glucose tolerance tests and none of our subjects presented with overt metabolic 
syndrome and so additional studies looking specifically at this metabolic parameter 
would be desirable. Overall diet quality, particularly as it relates to risk for increases in 
metabolic inflexibility should be considered when evaluating the nutritional impacts of 
individual diet components. It would also have been desirable to genotype subjects, 
albeit the cross-over design insured that all subjects participated in each test diet. Never 
the less genetic information may have provided additional insight into observed 
responses (195). 
Subject health status influenced HDL response to ground beef consumption as 
changes in HOMA-IR and HDL3-S1P were associated with subject baseline plasma lipid 
profile (162). Beneficial changes to measures of HDL quality appear to occur in 
response to lean components of beef and to be amplified by an increased MUFA:SFA.   
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CHAPTER III 
GROUND BEEF CONSUMPTION ALTERS HDL OXYLIPIN PROFILE IN 
HEALTHY MEN 
 
Introduction 
Oxylipins are a structurally and functionally diverse array of lipid mediators 
derived from PUFAs. Over the last decade, oxylipins have emerged as important 
regulators of inflammatory progress and have been implicated in various inflammatory 
conditions including type II diabetes, cardiac surgery, proteinuric hyperlipidemia and 
Immunoglobulin A nephropathy (76-79).  Oxylipins can be generated either via auto-
oxidation by ROS or via the actions of three enzyme families including COX, LOX, and 
CYP (80). Unlike COX derived oxylipins, that mainly occur in free forms, over 90% of 
LOX and CYP derived oxylipins in plasma are esterified in lipoproteins, with HDL 
containing the highest load for alcohols, epoxides and total oxylipins (90). Although it’s 
still unclear whether HDL oxylipins are mainly targeted for hepatic disposal or they can 
be released and act as lipid mediators, recent studies show that the unique HDL oxylipin 
profile can serve as a potential biomarker for inflammation and vascular health. In 
chronic inflammatory mice models, HDL oxylipin profiles were shown to possess 
increased pro-inflammatory oxylipin moieties including 5-HETE and 9-HETE, which 
are biomarkers for 5-LOX activation and auto-oxidation respectively (78). CYP derived 
epoxides are potent vasodilators. One recent study reported that increased HDL LA and 
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ALA derived epoxides are associated with improvements in microvascular function 
(196). 
Oxylipin profile is influenced by background diet, as dietary fats are modulators 
for tissue parent PUFA composition and the activities of the COX, LOX and CYP 
enzymatic pathways. One study investing the acute effects of high-fat diets on 
circulating oxylipins showed that a high MUFA diet increased postprandial CYP 
mediated oxylipins while high n-3 diet increased EPA and DHA derived oxylipins (197). 
In healthy human, supplementation of n-3 PUFA ethyl ester (P-OM3) resulted in 
elevated plasma n-3 PUFA derived oxylipins and reduced n-6 PUFA derived oxylipins 
(198). Interestingly, dietary fats appeared to have a differential effect on oxylipins in 
different lipoprotein compartments. Compared with AA derived oxylipins in LDL and 
VLDL, AA-oxylipins in HDL was less influenced by P-OM3 administration in 
hypertriglyceridemic, statin-treated subjects (199). On the other hand, HDL oxylipins 
have been reported to be more responsive to increased PUFA intake induced by walnut 
consumption than VLDL and LDL oxylipins in hypercholesterolemic women (196).  
As MUFA has been suggested to be more beneficial than SFA and that 
MUFA:SFA has a wide range in beef, our previous study evaluated the effect of 
MUFA:SFA ratio of beef fat on plasma lipids in 27 healthy free-living men. We reported 
that the consumption of 5, 114 g ground-beef patties containing 24% total fat of either 
high or low MUFA:SFA per week for 4 wk both resulted in an elevation in total and 
relative plasma AA concentrations despite an increase in HDL-C (162). It remains 
unknown whether the increased plasma AA or beef consumption is associated with 
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elevated ASCVD risk by giving rise to pro-inflammatory lipids. In the present study, we 
evaluated the effect of 24% total fat beef consumption on HDL oxylipin profile.   
Methods 
Subjects and design 
Banked plasma samples from 25 healthy men that successfully completed a 
randomized, cross-over beef feeding trial were used for the present study. The complete 
study design has been published (162). Briefly, the free-living participants consumed 
each of low MUFA and high MUFA beef diet for 5 wk in a random order with a 4wk 
wash out period between the diets. Each individual consumed five 114 g ground beef 
patties per week during the beef intervention period. The high MUFA ground beef 
patties, providing a MUFA:SFA = 1.10 were prepared from corn-fed Angus steers while 
the low MUFA beef patties, providing a  MUFA:SFA = 0.71 were prepared from 
pasture-fed Angus steers. The total fat content of both types of patties was formulated to 
be 24% by weight using fat and lean trims. During the feeding period, subject total fat 
intake increased an average of 10 g/d, increasing dietary fat energy percentage from 38% 
to 39.5% and total energy intake by 6.5% on average. Despite the slight increase in 
energy intake, no change in bodyweight for subjects was observed at the endpoint. Blood 
samples were collected from fasted men at the start and end of each feeding period. 
Isolated plasma samples were stored at -80°C prior to analysis.  
HDL oxylipin analysis 
HDL (d = 1.063-1.21 g/mL) was isolated from plasma by NaCl-NaBr sequential 
flotation ultracentrifugation and then sealed in nitrogen and stored at -20°C until 
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extraction. HDL esterified fatty acids (EFA) and oxylipins were extracted by solid phase 
extraction (200) and quantified by liquid chromatography-tandem mass spectrometry 
(76) as previously described with modifications (83). Briefly, 0.2 mg Na2EDTA/BHT 
was added to 250 μL of isolated HDL as anti-oxidants. The mixture was spiked with a 
set of deuterated oxylipin surrogates and subjected to hydrolysis in anhydrous sodium 
methoxide for 2 h at 60 ºC. The hydrolyzed lipids were diluted with 1 mL 95:5 (v/v) 
water:methanol with 0.1% acetic acid and then loaded onto the 60mg Oasis HLB SPE 
cartridges (Waters Corp, Milford MA) by gravity and air dried. The columns were 
wetted with 0.5 mL methanol and eluted with 2 mL ethyl acetate into polypropylene 
tubes containing 6 µL 30% glycerol in methanol. Samples were evaporated by 
centrifugal vacuum, reconstituted in 50 µL of methanol containing 100 nM of the quality 
control 1-cyclohexyl-ureido-3-dodecanoic acid (CUDA) and filtered with Durapore® 
PVDF 0.1 μm spin-filter tubes (Millipore, Billerica, MA) at 4°C. Then the extracted 
lipids were separated by reverse phase ultra-performance liquid chromatography (UPLC) 
using a 2.1 × 150 mm, 1.7 μm Acquity EBH column (Waters Corp, Milford MA). 
Analytes were detected on an ABI 4000QTrap (Applied Biosystems Inc., Foster City, 
CA) by multiple reaction monitoring (MRM) after negative mode electrospray 
ionization, tandem quadrupole mass spectroscopy (Micromass, Manchester, UK). 
Statistics 
Data analysis was performed using JMP 11.0 (SAS Institute Inc, Cary, NC). The 
distributions of variables were assessed by Shapiro-Wilk test and log transformations of 
skewed variables were used in subsequent analyses. HDL EFA and oxylipins at baseline 
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and after the consumption of low or high MUFA beef were compared by paired 
Student’s t test. Simple correlations were tested by Pearson or Spearman's correlation 
coefficient. Correlation network was visualized by Cytoscape (201). The level of 
significance was P <0.05. 
Results 
The present study was a secondary analysis of the original hamburger patty 
feeding study, with the complete feeding design published previously (162). A total of 
48 oxylipin compounds were detected in HDL. Their PUFA precursors included the n-6 
PUFA LA, DGLA and AA and the n-3 PUFA ALA, EPA and DHA. None of the 
concentrations of these EFA in HDL was altered after 5 wk consumption of both ground 
beef patties (Table 3.1).  
Overall HDL oxylipin distribution 
HDL oxylipins were primarily n-6 PUFA derivatives with ~75% oxylipins 
derived from LA, ~21% derived from AA and ~4% from n3 fatty acids, reflecting the 
distribution pattern of their parent PUFA (Table 3.2). LOX and CYP pathway represent 
two major lipid oxygenation pathways. Among all oxylipins, alcohols and their ketone 
metabolites from the LOX pathway dominated in concentration, followed by epoxides 
from the CYP pathway. The sEH metabolites diols and triols comprised less than 2% of 
total HDL oxylipins. While the concentration of total oxylipins remained unchanged 
after both beef interventions, a ~18% increase in the fractional abundance of DHA 
derived oxylipins was induced by both low (P = 0.02) and high MUFA (P <0.001) beef 
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patties. High MUFA beef also caused a ~2% decrease in total LA derived oxylipins (P = 
0.02) and a ~7% increase in AA derived oxylipins (P = 0.02).  
 
Table 3.1 HDL EFA composition at baseline and after 5 wk beef intervention 
FA type FA  Baseline  Low MUFA High MUFA 
  (μMol/100μMol EFA)     
SFA 16:0 23.7 ± 0.4 23.5 ± 0.4 23.6 ± 0.3 
 18:0   9.5 ± 0.1   9.4 ± 0.1   9.4 ± 0.1 
MUFA 16:1 n7   1.1 ± 0.1   1.0 ± 0.1   1.0 ± 0.1 
 18:1 n9 12.7 ± 0.3 12.4 ± 0.3 12.7 ± 0.3 
PUFA 18:2 n6 36.3 ± 0.7 37.1 ± 0.9 36.5 ± 0.8 
 18:3 n6   0.41 ± 0.03   0.37 ± 0.03   0.34 ± 0.02 
 18:3 n3   0.35 ± 0.02   0.36 ± 0.03   0.34 ± 0.02 
 20:3 n6   2.0 ± 0.1   2.0 ± 0.1   2.0 ± 0.1 
 20:4 n6 11.1 ± 0.3 11.0 ± 0.3 11.6 ± 0.4 
 20:5 n3   0.70 ± 0.09   0.71 ± 0.12   0.57 ± 0.05 
  22:6 n3   2.0 ± 0.2   2.0 ± 0.2   2.1 ± 0.2 
Data were expressed as mean ± SEM. n = 25. HDL EFA composition before and after 
beef intervention were compared by paired t-test. n3 PUFA were log transformed before 
statistical analysis. 
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Individual HDL oxylipin distribution 
The concentrations for individual HDL oxylipins at baseline and feeding 
endpoint were presented in Table 3.3. High MUFA beef consumption significantly 
reduced a number of LA derived oxylipins including the hydroperoxides 9-HpODE and 
13-HpODE, the diols 9,10-DiHOME and 12,13-DiHOME, the triol 9,12,13-TriHOME 
and the ketones 9-KODE, 13-KODE and EKODE. The metabolic pathway for these LA-
oxylipins were shown in Figure 3.1. High MUFA beef also decreased AA-ketone 5-
KETE and EPA-epoxide 14(15)-EpETE while the concentration of DHA-epoxide 
19(20)-EpDPE increased. The fold changes from baseline for these oxylipins induced by 
high MUFA beef ranged from 10-23%. In contrast, low MUFA beef only decreased the 
concentration of 5-KETE by ~12% with no effect observed on other individual 
oxylipins. To examine whether the changes in the concentration of oxylipins were 
caused by possible alteration in the activities of sEH and hydroxyl fatty acid 
dehydrogenase, ratios of ketones:alcohols and diols:epoxides were calculated. Results 
showed that high MUFA beef significantly decreased the ratio of diol:epoxide from 
0.037 to 0.031 when compared with baseline. While high MUFA beef consumption 
appeared to have a more profound effect on HDL oxylipin profile, no significant 
difference was observed for all measured oxylipin variables after two beef diets. 
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Correlations between changes in HDL oxylipins and ASCVD risk factors 
In our previous study, we reported that beef consumption non-differentially 
raised HDL3-S1P and improved insulin sensitivity in the same study population. 
Correlation analysis showed that a greater increase in HDL3-S1P was associated with a 
greater reduction in HDL 5-KETE after beef consumption (Figure 3.2). No correlation 
was observed for the change in insulin sensitivity with any change in HDL oxylipins 
(data not shown).  
Correlations between changes in HDL oxylipins and baseline HDL EFA  
As background diet, especially n3 fat intake, may affect oxylipin formation, we 
analyzed the correlation between baseline HDL EFA and beef induced changes in 
oxylipins. No effect of baseline HDL SFA, MUFA or n-6 PUFA on concentration 
change in oxylipins was observed. However, the magnitude of changes for half of the 
oxylipins whose concentration was influenced by beef consumption was associated with 
background HDL n-3 PUFA. All significant correlations are shown in Figure 3.3. 
Baseline ALA was negatively associated with LA derived diols 9,10-DiHOME (P = 
0.040) and 12,13-DiHOME (P = 0.002). Baseline EPA was associated positively with 
the change in the AA ketone metabolite 5-KETE (P = 0.008) and negatively with the 
change in AA epoxide metabolite 14(15)-EpETE (P = 0.003) while baseline DHA was 
positively correlated with the changes in LA ketone metabolites EKODE (P = 0.036) 
and 13-KODE (P = 0.037).   
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Figure 3.2 Pearson correlation between the changes in HDL3-S1P and HDL 5-KETE by 
beef consumption. 
 
 
 
Figure 3.3 Spearman correlation between baseline HDL EFA and beef induced changes 
in HDL oxylipins. Changes (endpoint-baseline) in 5-KETE included data from both low 
and high MUFA beef interventions. Changes in other oxylipins only included data from 
high MUFA intervention. *P <0.05; **P <0.01. 
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As no significant differences were observed for HDL oxylipins after the two beef 
diets, data were combined for correlation analysis. Pearson correlation matrix was 
calculated for oxylipin metabolites (Figure 3.4). As shown by the heat map, oxylipin 
regioisomers generally shared similar correlations with other oxylipins. For 
summarization and visualization purpose, oxylipins were grouped according to oxylipin 
class and their parent fatty acids, with median correlation coefficients within the groups 
of related metabolites calculated (Figure 3.5). At baseline, LOX pathway products were 
highly interdependent. Hydroperoxides were strongly correlated with all the down-
streaming LOX products derived from n6 PUFA including alcohols (r = 0.41, (0.34, 
0.49), median (1st quantile, 3rd quantile)), ketones (r = 0.74, (0.66, 0.87)), and triols (r = 
0.39, (0.38, 0.42)). n6 PUFA derived alcohols were strongly associated with the down-
streaming ketones (r = 0.50, (0.44, 0.60)) and triols (r = 0.48, (0.39,0.68)), as well as n3 
PUFA derived alcohols (r = 0.62, (0.52, 0.70)). Relatively weaker correlations were 
observed between LOX pathway products and CYP pathway products. The median 
correlation coefficients for n6 PUFA derived epoxides with n6 PUFA derived 
hydroperoxides, alcohols, ketones were r = 0.39 (0.28, 0.47), r = 0.25 (0.18, 0.34), r = 
0.30 (0.25, 0.34) respectively. The beef diet intervention greatly disrupted the 
interdependencies between LOX pathway products. The only strong correlations 
remained after beef consumption were the correlations between n6 PUFA derived 
hydroperoxides and ketones (r = 0.68, (0.60, 0.79)), and the correlations between n6 and 
n3 PUFA derived alcohols (r = 0.73, (0.68, 0.83)). On the other hand, the correlations  
between LOX and CYP products were relatively less influenced. The correlations 
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Figure 3.4 Pearson correlation matrix for HDL oxylipin metabolites before (above the 
diagonal) and after (below the diagonal) 5 wk beef patty intervention. Correlations with 
a |r| ≥0.23 were significant. 
 
 
 
Figure 3.5 Correlation network for HDL oxylipin metabolites before and after 5 wk beef 
patty intervention. Median correlation coefficients within the groups of related 
metabolites were displayed. Only correlations with a median |r| ≥0.21 were included in 
the network graph. Size of the rectangle reflected the relative abundance of the oxylipin 
group. 
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between n6 PUFA derived epoxides with n6 PUFA derived hydroperoxides and ketones 
appeared to slightly increased, from 0.39 (0.28, 0.47) to 0.46 (0.34, 0.52), and 0.30 
(0.25, 0.34) to 0.42 (0.36, 0.47) respectively. 
Discussion 
Oxylipins are lipid mediators which play important roles in inflammation and 
immune homeostasis. HDL is a major carrier for circulating oxylipins and has displayed 
distinctive oxylipin profile compared with VLDL and LDL, suggesting it may provide a 
different predictive value for disease than total circulating oxylipins. Here we 
demonstrate for the first time that ground beef consumption decreases the pro-
inflammatory 5-KETE in HDL particles in healthy individuals regardless of beef fatty 
acid composition and that oxylipin response to ground beef is influenced by baseline n3 
status. 
The AA derived 5-KETE is oxidized from 5-HETE by 5-hydroxyeicosanoid 
dehydrogenase (5-HEDH). 5-HEDH is expressed in various inflammatory and structural 
cells including neutrophils, monocytes and endothelial cells. 5-HEDH has extremely 
high substrate selectivity and is regulated by oxidative stress (202). The pro-
inflammatory and oxidative stress induced chemoattractant 5-KETE is nearly 100 times 
more potent than 5-HETE and can stimulate eosinophil migration (203, 204). A 
reduction in HDL 5-KETE was induced by both high and low MUFA beef, suggesting 
this effect may be attributed to the lean portion of beef. Our previous study showed that 
5 wk beef consumption significantly raised S1P in HDL3 per se. S1P is a signaling 
molecular that mediated various HDL atheroprotective functions including inhibiting 
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ROS production and MCP-1 secretion from endothelium (12) as well as promoting NO-
dependent vasorelaxation (16). Here we demonstrated that the reduction in HDL 5-
KETE is inversely correlated with the increase in HDL3 S1P. One possible underlying 
mechanism is that the activity of 5-HEDH requires NADP+ as a cofactor (203) and the 
inhibition of NADPH oxidase by HDL-S1P (12) may inhibit the enzymatic activity of 5-
HEDH and thus decreasing the synthesis of 5-KETE. Interestingly, the auto-oxidation 
marker 9-HETE was not altered after both beef diets, indicating a differentiation 
between enzyme-mediated and auto-oxidation products. Our previous study showed that 
HOMA-IR was also altered by both beef diets. No correlation was observed between 
insulin sensitivity and oxylipin profile change in healthy men. This result in some way 
supported one study that investigated the associations between insulin sensitivity and 
postprandial oxylipin profile change and observed no significant association in healthy 
subjects (197). As the oxylipin profile in healthy controls varied considerably from 
diabetic patient, it’s possible that there’s a threshold effect of insulin sensitivity on 
oxylipin profile (93).  
After high MUFA beef consumption, all detected HDL hydroperoxides showed a 
tendency to decrease with significant P values observed for LA-derived hydroperoxides 
and marginal P values observed for AA-derived hydroperoxides. HDL has been reported 
as the predominant carrier for plasma hydroperoxides in mice models of atherosclerosis 
(205) and human (206). While HDL contains various anti-oxidant enzymes with PON1 
being able to eliminate peroxidized phospholipid, our previous data showed that PON1 
activity was not altered after beef consumption. The decrease in hydroperoxides may 
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result from a decreased formation, which can be achieved either through down-
regulation of LOX pathway or the reduction in the availability of reactive oxygen 
species (144). The fractional abundance of both diols and triols were reduced by high 
MUFA beef consumption. While diol oxylipins were known to be generated from the 
CYP pathway and triol metabolites from the LOX pathway, they are both formed 
through the direct action of sEH from respective epoxide and hydroperoxide precursors 
(207). The ratio of plasma DiHOMEs to EpOMEs has been reported as a reliable 
biomarker for sEH activity (208). In the present study, the ratio of HDL DiHOMEs to 
EpOMEs significantly decreased. However, it was unclear whether it was due to reduced 
cellular production of diols and triols or reduced retention of these oxylipins in HDL. It 
should be noted that the high MUFA beef induced reduction in the fractional abundance 
of diol was caused by the reduction in absolute HDL DiHOME concentration. LA-
derived diols have been shown to possess cytotoxic effects and can cause vascular 
endothelial cell dysfunction (209, 210). A reduction in diol synthesis may imply 
atheroprotective effects. High MUFA beef consumption also diminished the 
concentrations of the less well studied LA-derived ketone metabolites 9-KODE, 13-
KODE and EKODE in HDL. Plasma oxylipin profile in in type 2 diabetic patients 
displayed elevated EKODE and 13-KODE content (93).  
Basal n3 FA status has been previously shown to modulate oxylipin response to 
n3 FA administration in both norm- and hyper-lipidemic healthy individuals (211, 212). 
Here we report that n3 FA status also influences HDL oxylipin response to beef diets, 
though the effect was not universal (ie. suppression of all n6 PUFA derived oxylipins). 
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Importantly, we observed a positive correlation between basal EPA and the reduction in 
5-KETE. High dose DHA+EPA supplements have been reported to down-regulate the 
gene expression of ALOX5 in peripheral blood mononuclear cells (213). If overall 5-
LOX pathway activity was already low in subjects with high basal n3 FA, a diminishing 
5-KETE response may be expected as the subject was in optimal health. In fact, greater 
reduction was observed in subjects with higher baseline 5-KETE (data not shown). On 
the other hand, our results clearly showed that n3 FA of differing chain length had 
differing effects on oxylipin profile and thus provide evidence that composition of n3 
PUFA may be of relevance to maximize the health benefits of n3 supplements. 
The majority of previous diet-oxylipin relation studies are focused on the effect 
of parent PUFA manipulation on plasma oxylipin profile, especially by using n3 FA 
supplementation (83, 199, 211, 212, 214, 215). Our study was initially conducted as 
plasma total AA was increased after both beef diets. Interestingly, we observed no 
change in total HDL esterified AA or AA derived oxylipins, nor any significant 
correlation between the increase in plasma AA with the change in individual oxylipin 
class (data not shown). These observations suggest the effect of beef consumption on 
HDL oxylipin profile are independent of parent PUFA modulation. Human AA are 
distributed between tissue and membrane compartments with varying turnover rate and 
physiological function (216). Indeed, a series of human dietary AA supplementation 
study have showed that AA phospholipids in adipose tissue could remain unchanged 
despite a two-fold increase in plasma (217). Currently, little is known about the main 
tissue PUFA pool for oxylipin generation and the source for HDL oxylipins. AA 
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enrichment in meat product has been a health concern as they could give rise to pro-
inflammatory lipid mediators. As HDL is the major AA oxylipin carrier in plasma (199), 
our study offer evidence that short-term beef consumption induced moderate AA intake 
increase may not translate into increased pro-inflammatory oxylipin production in 
healthy subjects. On the other hand, our study showed that beef consumption greatly 
reduced the interdependencies between LOX pathway products, possibly by inducing 
differing effect on down-steaming oxylipin metabolizing enzymes. Similar reduction of 
interdependency of HDL oxylipins was observed by P-OM3 administration in a previous 
study, illustrating of the complexity of oxylipin profile regulation (199).  
In summary, this study showed that regular consumption of a serving of a 
moderate fat ground beef significantly decreased the pro-inflammatory 5-KETE in HDL 
in healthy subjects. This effect was independent of ground beef fatty acid composition, 
but was dependent of individual basal n3 FA status. MUFA content in high MUFA beef 
appear to have additional health benefits, but the effect is moderate as no significant 
difference was observed for endpoint oxylipin profile for low and high MUFA beef 
diets. The present study is a pilot study on dietary modulation of HDL oxylipins. Further 
knowledge about the kinetics of oxylipin formation, transportation and turnover 
(possibly with isotopic tracer studies) as well as genetic typing of the subjects will vastly 
improve our understanding of our results. 
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CHAPTER IV 
METABOLIC INFLEXIBILITY LIMITS REDUCTIONS IN SMALL DENSE 
LDL DUE TO LEAN BEEF CONSUMPTION 
 
Introduction 
LDL particles are highly heterogeneous in terms of atherogenicity due to the 
variations in size, composition and physiochemical properties. Compared with larger 
LDL particles, small dense LDL (sdLDL) particles have a higher propensity to penetrate 
the artery wall and bind to proteoglycans (218), increased susceptibility to oxidation 
(219) and reduced affinity for the LDL receptor (220). Thus, sdLDL particles are an 
independent risk factor for CHD (221).   
Intervention studies have shown that LDL density distribution is modulated by 
dietary macronutrient composition. Compared with an iso-caloric high fat diet, low 
fat/high carbohydrate diets are associated with either no change or a decrease in LDL 
particle size (222-226). The difference among studies could be due, in part, to 
differences in type and amount of carbohydrate used in the studies. Replacement of 
carbohydrate by protein (from plants or mixed sources) in moderate or high fat eucaloric 
diets is generally associated with an improved LDL density profile (225, 227). While 
soy, as a protein source, has been more extensively studied and shown to improve the 
LDL density profile (228, 229), little is currently known about the effect of animal 
protein (and different animal proteins) on LP density distribution. A high degree of 
within-study variation in individual LDL particle responsiveness has been consistently 
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reported, even under controlled feeding conditions, suggesting the influence of genetic 
and other environmental factors on the responsiveness of LDL particles. ApoE 
phenotype (222) and small LDL subclass pattern (226) have both been identified as 
determinants of LDL response to low fat diets.  
The DASH dietary pattern is considered a gold standard heart healthy diet that 
features fruits and vegetables as well as reduced SFA, cholesterol and red meat (163, 
164). While some epidemiological studies reported adverse health associations for red 
meat, this may be attributed to the SFA intake, varying levels of meat processing and 
additives, and/or residual confounding factors (145). To test whether lean beef could be 
included in a heart healthy diet, the BOLD study compared the cholesterol lowering 
effects of a DASH dietary pattern with two DASH-like dietary patterns that provided 
different amounts of lean beef when consumed by a mildly hypercholesterolemic 
population (165, 230). The primary outcome of that trial was the significant (and similar) 
reduction in total-C and LDL-C in the DASH and lean beef containing diets compared to 
the HAD control diet (165). In addition, the higher protein/higher lean beef diet was the 
only dietary intervention to elicit a significant reduction in systolic blood pressure 
compared to the control diet (230). The aim of this secondary analysis was to determine 
the effect of dietary patterns that varied in the amount of dietary protein provided by lean 
beef on LP density distribution and the prevalence of sdLDL. In addition, inflammatory 
status and insulin sensitivity have both shown to affect lipoprotein particle size 
modulation (231). The secondary aim was to assess whether baseline health status 
affected the dietary responsiveness of LP density distribution.  
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Methods 
Subjects and design 
The present study is a secondary analysis of 27 complete sample sets available 
from the original BOLD study. The detailed design has been published (165). Briefly, 
plasma samples were taken from healthy men and women (36-65 y of age) with 
moderately high baseline LDL-C (2.47-4.83 mmol/L). No lipid-lowering medications or 
dietary supplements were taken at baseline and during the study. The BOLD study 
evaluated the effects of four diets: HAD (control), DASH, BOLD and BOLD+ (Table 
4.1). Subjects consumed each of the four test diets for 5 wk in a random order in a 
controlled-feeding setting with a minimum on a 1-wk compliance break between the 
diets. The HAD was higher in SFA and total fat. It also included more refined grains, 
added sugars, and full-fat dairy products compared to the test diets. The DASH, BOLD 
and BOLD+ diets included more whole grains, vegetables, fruits, and low-fat dairy 
products. The DASH and BOLD (28 g/d vs. 113 g/d lean beef) were matched for 
macronutrient energy distribution, but differed in protein source. BOLD+ was similar to 
BOLD and DASH, but contained greater amounts lean beef (153 g/d) and protein (27% 
vs. 18-19% energy, respectively). The total energy content of the test diets was 
individually adjusted to keep participants’ weight stable during the feeding periods. 
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Table 4.1 Energy and macronutrient profiles of the study diets 
  HAD DASH BOLD  BOLD+ 
95% lean Beef (g/day) 20 28 113 153 
Calories (kcal) 2097 2106 2100 2104 
Protein (%E) 17 18 19 27 
Carbohydrate (%E) 50 55 54 45 
Fat (%E) 33 27 28 28 
SFA (%E) 12 6 6 6 
MUFA (%E) 11 9 11 12 
PUFA (%E) 7 8 7 7 
 
 
Laboratory measurement 
Insulin sensitivity was estimated by HOMA score (174) and calculated from 
previously measured plasma and insulin concentrations. LP density profile was 
determined by imaging of fluorescently stained lipoproteins following NaBiEDTA 
ultracentrifugation as previously described with modifications (232). Briefly, 6 µL 
plasma was incubated with 10 µL 1g/L NBD-C6-ceramide, and 1184 µL 0.18 mol/L 
NaBiEDTA density gradient solution. A volume of 1150 µL of this mixture was then 
transferred to an 11 x 34 mm thickwall polycarbonate tube and centrifuged in a 
Beckman Optima MAX-XP centrifuge equipped with a MLA-130 rotor (Beckman 
Coulter, Inc. Brea, CA) for 6 hr at 4ºC. Following gentle overlayment of hexane, the 
tubes were immediately imaged by a CCD camera (Quantifire XI, Optronics, Muskogee, 
OK) with a Fiber-Lite Illuminator (MH100A, Edmund Industrial Optics, Barrington, NJ) 
as light source. The tube holder, digital camera and illuminator were positioned 
orthogonally to each other on an optical bench. The respective filters (Semrock, 
Rochester, NY) were chosen to match NBD excitation (465 nm/60 nm bandwidth, part # 
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FF01-460-60-25) and emission (>500 nm/long pass, part # BLP01-488R-25) 
wavelengths, respectively. Pixel values of the center of the tube were converted into 
fluorescent intensity using Origin 7.5 (OriginLab Ltd, Northampton, MA) software and 
plotted as a function of the tube coordinate. A total of 10 LP subclasses were identified 
by their density intervals (131, 134), and quantified by calculation of area under curve 
(AUC, i.e. pixel value). The major LP subclasses are TRL (d <1.019 g/mL), LDL1 (d = 
1.019-1.023 g/mL), LDL2 (d = 1.023-1.034 g/mL), LDL3 (d = 1.034-1.044 g/mL), LDL4 
(d = 1.044-1.063 g/mL), HDL2b (d = 1.063-1.091 g/mL), HDL2c (d = 1.091-1.110 g/mL), 
HDL3a (d = 1.110-1.133 g/mL), HDL3b (d = 1.133-1.156 g/mL) and HDL3c (d = 1.156-
1.179 g/mL). 
Methodology was validated by measuring intra- and inter- assay reproducibility 
of samples differing in TG concentration. Subjects were divided into quintiles based on 
plasma TG concentration. Three plasma samples from each of the 1st, 3rd, 5th quintiles 
were randomly selected and pooled and used as low (55.6 mg/dL), medium (102.2 
mg/dL) and high TG (199.3 mg/dL) TG concentration samples. For intra-assay variation 
assessment, 3 replicates for each of the low, medium and high TG samples were 
analyzed in a single run. For inter-assay variation assessment, 5 replicates of the samples 
were run on 5 separate days. On each day, a set of low, medium and high sample was 
analyzed.  
Statistics 
Statistical analysis was performed using JMP 10.0 (SAS Institute Inc., Cary, 
North Carolina). All data were assessed for normality using Shapiro-Wilk test. Data with 
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a skewed distribution were log transformed before subsequent analysis. Baseline 
characteristics between men and women were compared by unpaired t-test. 
Measurement of LP subclass by NBD-C6 ceramide distribution was compared with 
conventional chemical measurements from Roussell (165) using Pearson correlation. 
The LP density distribution and HOMA-IR at baseline and after each of the 4 test diets 
were compared by repeated measures ANCOVA with adjustment for age, gender and 
BMI, followed by Tukey-Kramer test. The primary outcome was the difference in 
absolute and fractional abundance of small dense LDL4 after the consumption of 
BOLD+ diet compared to LDL4 abundance following the consumption of HAD diet. 
Pearson correlation coefficients were calculated for the BOLD+ diet induced change in 
LDL4 to changes in previously reported lipid variables and apolipoprotein 
concentrations. To examine the effect of baseline lipids, inflammation indicators and 
insulin sensitivity on LDL4 response to test diets, Pearson correlation coefficient was 
calculated for baseline TG, TC, LDL-C, HDL-C, HOMA-IR and CRP with percentage 
change of LDL4 from baseline for each test diet. When a significant correlation was 
observed for baseline HOMA-IR and LDL4 percentage change, a secondary analysis was 
performed to better characterize the effect of baseline HOMA-IR. Subjects with baseline 
HOMA-IR below the median were classified as low HOMA-IR group (n = 13) and those 
with HOMA-IR equal or greater than the median were classified as high HOMA-IR 
group (n = 14). Since there was more individual variation in LDL4 response observed 
among subjects with high baseline HOMA-IR, as judged from standard deviation, the 
median was included in the high HOMA-IR group in the analysis. However, the 
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inclusion or removal of the median from either the low or high HOMA-IR group had no 
effect on the significance of any tests. To investigate the responsiveness to test diets 
within each baseline HOMA-IR subgroup, mixed model repeated measures analysis was 
performed with subjects entered as a random variable and age, gender and BMI as 
covariates. When a significant overall dietary effect was detected by the mixed model, 
Tukey-Kramer test was used to further investigate the difference between diets. The 
level of significance was P <0.05. Tabular values were expressed as mean ± SEM. 
Results 
Baseline characteristics 
Baseline characteristics of the 27 subjects that had complete sample sets from the 
original 36 (165) are shown in Table 4.2. The subjects were mildly hypercholesterolemic 
but were within the normal range for TG (<150 mg/dL) and HDL-C (>40 mg/dL for men 
and >50 mg/dL for women) concentrations. Females had a significantly higher average 
total-C (P = 0.003) and LDL-C (P = 0.007) than males. No difference was observed for 
TG, HDL-C, CRP and HOMA-IR between men and women. Despite the difference in 
total LDL-C concentration between men and women, the difference was mainly due to 
the presence or more large and medium LDL in women (Figure 4.1) but not small dense 
LDL4. No significant gender effect on LDL4 response to the test diets was observed.  
LP density distribution 
LP density distribution was measured using a slight modification of a isopycnic 
separation of lipoproteins fluorescently dyed with NBD-C6-ceramide followed by digital 
analysis (232). NBD-C6-ceramide is only fluorescent under hydrophobic environment. 
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Table 4.2 Baseline characteristics of BOLD Study subjects 
  Men (n = 10)  Women (n = 17) Total (n = 27) 
 Age (y) 50.9 ± 2.6 50.9 ± 2.2 50.9 ± 1.7 
 BMI 26.5 ± 0.8 25.1 ± 0.9 25.6 ± 0.6 
 TG (mg/dL) 95.6 ± 8.9 97.1 ± 7 96.5 ± 5.4 
 Total-C (mg/dL) 192.3 ± 5.6 225.6 ± 7 213.3 ± 5.8 
 LDL-C (mg/dL) 125.7 ± 5.2 150.1 ± 5.5 141 ± 4.6 
 HDL-C (mg/dL) 47.6 ± 2.6 56.1 ± 3.9 52.9 ± 2.7 
 HOMA-IR 2.8 ± 0.3 2.7 ± 0.2 2.7 ± 0.2 
 CRP (mg/L) 1.5 ± 0.5 1.2 ± 0.3 1.3 ± 0.3 
Data expressed as mean ± SEM.  
 
 
Thus, the fluorescent intensity of a particle depends on the quantity of the hydrophobic 
group/molecules on lipoprotein particle surface, allowing an estimation of total mass.  
The AUC of core-lipid rich TRL, LDL and HDL2 were strongly correlated with plasma 
TG, LDL-C and HDL-C, respectively (r ≥0.66, P <0.0001, Figure 4.2A-C). For core 
lipid-poor HDL3, there was a significant but weaker association with HDL-C (r = 0.27, P 
= 0.007, Figure 4.2D). Since small HDL3 contains little cholesterol ester per se, only a 
weak, but significant association was observed for the HDL3 AUC and HDL-C.  The LP 
density distribution demonstrated that technical variations across different LP subclasses 
were similar for samples containing differing amounts of TG, with the highest variation 
occurring at the top and bottom of the regions of the tube (i.e. TRL, LDL1, and HDL3c 
subclasses). The increase in variability was likely due to the specific solution 
redistribution condition at these positions during centrifuge deceleration. For other LP 
subclasses, the average CV% was as low as 5% with 3 replicates for intra-assay 
assessments and 4% with 5 replicates for inter-assay assessments (Table 4.3). 
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A. 
 
B. 
 
Figure 4.1 LP density profile for male and female subjects at baseline and after the 
dietary intervention. The BOLD+ diet was used as an example. No significant gender 
effect on LDL4 distribution was detected.  
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A                                                                 B 
  
C                                                                 D 
 
Figure 4.2 Correlations between LP density profile and biochemical measurements in 135 
samples. Linear regression, correlation coefficient and P value are shown for each 
comparison. TG and TRL AUC data were log transformed to achieve normality.  
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Table 4.3 Reproducibility for intra- and inter-assay 
  Intra-assay (n = 3)   Inter-assay (n = 5) 
TG Low Medium High  Low Medium High 
LP distribution calculated as absolute AUC     
TRL 18.6 13.9 14.9  19.8 11.3 10.6 
LDL1 33.6 21.8 12.9  32.6 21.7 8.2 
LDL2 10.1 5.7 8.6  11.3 6.8 4.1 
LDL3 2.4 5.1 8.0  2.9 4.4 4.7 
LDL4 6.2 9.4 8.4  5.4 5.1 7.6 
HDL2b 1.5 4.6 6.4  0.2 1.4 2.9 
HDL2a 3.4 4.7 6.1  2.0 1.5 0.4 
HDL3a 3.2 4.6 4.4  1.9 1.7 1.9 
HDL3b 4.3 3.3 1.8  3.0 3.4 6.8 
HDL3c 13.9 10.8 9.3  14.4 9.5 13.4 
Average 9.7 8.4 8.1  9.3 6.7 6.1 
LP distribution calculated as % total AUC    
TRL 10.8 8.8 22.9  9.6 8.8 19.1 
LDL1 21.9 19.2 12.2  21.4 18.1 11.2 
LDL2 5.9 4.3 8.0  4.4 3.4 4.1 
LDL3 5.0 5.6 3.9  5.1 4.9 5.5 
LDL4 4.3 4.3 5.9  3.4 3.5 4.5 
HDL2b 3.2 1.9 7.2  2.2 1.9 5.9 
HDL2a 8.7 4.2 3.8  7.7 5.0 5.8 
HDL3a 6.1 2.3 4.3  5.5 3.4 3.8 
HDL3b 4.6 2.0 7.3  4.2 0.8 4.0 
HDL3c 11.7 8.4 9.9  9.9 8.2 6.1 
Average 8.2 6.1 8.5   7.3 5.8 7.0 
Coefficients of variation for intra-assay and inter-assay. Low TG = 55.6 mg/dL, medium 
TG = 102.2 mg/dL; high TG = 199.3 mg/dL. 
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Compared with baseline, no absolute or fractional change was observed for any 
LP subclass after the consumption of the HAD diet (Table 4.4). For this reason, we 
assumed that macronutrient distribution of the subjects’ baseline diet was similar to 
HAD. Compared with the control HAD diet, BOLD+ significantly reduced total small 
dense LDL4 AUC by ~9.2% which also caused a reduction in the fractional abundance 
of LDL4 (P <0.05), indicating a shift in LDL particle diameter distribution towards 
larger sizes. Further analysis demonstrated that when subjects consumed the BOLD+ 
dietary pattern, the induced decrease in LDL4 paralleled the decrease in TC (r = 0.48, P 
= 0.014), LDL-C (r = 0.55, P = 0.004) and ApoB (r = 0.68, P <0.001), with the strongest 
association observed for ApoB. Despite the lack of a significant difference in TG after 
the consumption of the HAD and BOLD+ diets, we observed a positive correlation 
between the change in TG and LDL4 (r = 0.41, P = 0.044). Total HDL2b AUC was 
significantly decreased by ~5.6% and ~6.8% after the consumption of the DASH and 
BOLD diets, respectively (P <0.05), but not after consumption of the BOLD+ diet. The 
fractional abundance of HDL3a increased following consumption of any of the three test 
diets low in saturated fat (i.e. DASH, BOLD and BOLD+) compared to the proportion 
present following consumption of the HAD (P <0.05).
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HOMA-IR 
Average HOMA-IR did not differ from baseline following any of the four test 
diets (Table 4.2), being 2.76 ± 0.20 following consumption of HAD, 2.64 ± 0.13 
following DASH, 2.93 ± 0.17 following BOLD and 2.94 ± 0.17 following BOLD+.  
LDL4 responsiveness 
To identify the possible predictors for individual LDL responses to shifts from 
baseline to HAD or the DASH-like lower SFA diet, simple correlations were calculated 
for the percentage change in LDL4 from baseline with baseline lipid variables, HOMA-
IR and CRP. The results showed that increased baseline HOMA-IR was strongly 
associated with a less favorable LDL4 response to the DASH (r = 0.56, P = 0.003) and 
BOLD (r = 0.47, P = 0.018) test diets (Table 4.5). Marginally significant correlations 
were also observed for baseline HOMA-IR (r = 0.36, P = 0.065 and baseline CRP (r = 
0.35, P = 0.093) with LDL4 response to HAD. To better assess the effect of baseline 
HOMA-IR on the LDL4 response, subjects were divided into low and high baseline 
HOMA-IR groups by median split. Subjects with low baseline HOMA-IR had a 
significant decrease in LDL4 after the consumption of the BOLD (P = 0.003) and 
BOLD+ (P = 0.046) diets and a non-significant decrease after the consumption of DASH 
(P = 0.069) (Figure 4.3). The responsiveness to the four test diets showed no significant 
difference (P = 0.890) in the low baseline HOMA-IR group. In contrast, subjects with 
high baseline HOMA-IR showed no change in LDL4 after consumption of the DASH, 
BOLD, and BOLD+ diets.  The LDL4 response to the BOLD+ diet was significantly 
different from the HAD and DASH diets in the high HOMA-IR group (P = 0.013).  
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Figure 4.3 Effects of baseline HOMA-IR on LDL4 response. Low and high baseline 
HOMA-IR subgroups were classified by median split. Values were expressed as mean ± 
SEM. Within each subgroup, diet induced LDL4 percentage changes from baseline were 
compared by repeated measures ANCOVA with age, gender and BMI adjusted. 
Different letters indicate significant difference in response to diets (P <0.05). An 
unbracked asterisk indicates significantly different from zero (P <0.05). A bracketed 
asterisk indicates marginally different from zero (P <0.1). 
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Discussion 
In the present study, we found that increasing dietary protein, from lean beef and 
other protein sources, while decreasing carbohydrate in a DASH-like dietary pattern 
improved LP density profile by decreasing the absolute and proportional abundance of 
sdLDL (LDL4) when compared to a HAD. The DASH and BOLD diets also appeared to 
have beneficial effects on the LDL density profile. However, these effects were modified 
by baseline HOMA-IR of the subjects. To the best of our knowledge, this is the first 
study that showed baseline metabolic flexibility modulates the sdLDL response to a low 
SFA dietary intervention. 
Small dense LDL4 was decreased by 9.6% after consumption of the BOLD+ 
versus the HAD. It has been previously reported that the BOLD+ diet induced a 6% 
reduction in LDL-C; the present density distribution analysis identified a preferential 
decrease in the small and what is thought to be the most atherogenic LDL subfraction. In 
this analysis, LDL4 particles were defined as those with a density range of 1.044-1.063 
g/mL, which roughly corresponds to LDL particles with a diameter smaller than 24.2 nm 
measured by non-denaturing gradient gel electrophoresis (233). The large prospective 
Quebec Cardiovascular Study with over 2,000 men found that participants in the third 
tertile of absolute or relative cholesterol in LDL particles with diameters smaller than 
25.5 nm had over a 4-fold increase in the risk of ischemic heart disease compared with 
men in the first tertile after adjustments for other lipid and non-lipid risk factors (221). 
These observations suggest that even a modest reduction in sdLDL concentration may be 
of significant benefit for CVD risk reduction. Our finding that LDL density distribution 
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was only changed by the BOLD+ diet, but not the DASH and BOLD diets, suggests that 
the BOLD+ diet induced improvement in LDL density profile was partially mediated by 
the replacement of carbohydrates with protein in addition to the effects of SFA 
reduction. Despite the difference in protein source, this finding is consistent with earlier 
observations that replacement of carbohydrate by protein in a low SFA diet can improve 
the LP profile by shifting LDL to larger particle size (225, 227, 234). The underlying 
mechanism for the decrease in sdLDL by the BOLD+ diet is unclear, but possibly 
involves alteration in TG metabolism, as shown by our correlation analysis. Higher 
VLDL ApoB secretion, lower VLDL ApoB fractional transfer rate (FTR), as well as a 
lower LDL ApoB fractional catabolic rate (FCR) have been observed in healthy men 
with predominantly small, dense LDL (pattern B)(235). 
Our secondary analysis showed that a significant decrease in sdLDL occurred 
only in subjects with higher baseline metabolic flexibility, as indicated by low HOMA-
IR values, after consumption of the DASH and BOLD diets. One earlier study of 86 
healthy men, using Step I and Step II diets reported that high baseline HOMA-IR 
unfavorably affected the change in total LDL cholesterol in those subjects (236). We 
extended these findings by showing that baseline HOMA-IR also influences the change 
in LDL density distribution in response to low saturated fat, high carbohydrate diets. 
This observation may help explain inconsistencies in different studies. In a controlled 
feeding study of 24 hypercholesterolemic men and women, a Step II diet enriched in 
whole grains, vegetable and fruits decreased LDL particle size compared with a higher 
fat “healthy American diet” (237). Since our subjects were younger and had much 
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milder dyslipidemia, a potential difference in metabolic flexibility may account for the 
differences in study outcomes. Notably, the subjects in the BOLD study had fasting 
glucose and insulin concentrations that were within normal limits (165). Interestingly, 
similar responses to the BOLD+ diet for sdLDL were observed for low and high baseline 
HOMA-IR groups. Metabolic inflexibility is associated with postprandial hyperglycemia 
which promotes ApoB glycation and decreases the affinity of ApoB for LDL-R (238); 
sdLDL is also the subclass most susceptible to glycation (239). Compared with DASH 
and BOLD diets, BOLD+ had a higher proportion of protein and a lower glycemic load, 
and thus may attenuate the glycation of LDL, especially in subjects with decreased 
metabolic flexibility. 
Amounts of larger diameter HDL2b were decreased following consumption of the 
DASH and BOLD dietary patterns when compared to HAD. This observation was 
consistent with a previous report that the most pronounced HDL response to a low fat 
and SFA diet is the decrease in large HDL2 and HDL2b in healthy subjects (240). 
Turnover studies have showed that low fat diets decrease the transport rate and increase 
the FCR of ApoA-I while dietary fat has the opposite effect (241, 242). The FCR of 
ApoA-I is reported to be inversely associated with HDL particle size (243). Caution 
should be taken in interpreting the decrease in large HDL2b by low fat diets as HDL 
possess anti-inflammatory and anti-oxidative functions in addition to cholesterol efflux, 
which have not been fully explored. BOLD+ appeared to modestly reverse the 
significant decrease in absolute HDL2b concentration caused by the DASH and BOLD 
dietary patterns, though the magnitude was not large enough to prevent a shift in HDL 
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towards smaller particles. Apolipoprotein measurements in the original BOLD study 
showed that HDL ApoC-III was significantly reduced by BOLD+ compared with HAD 
(165). ApoC-III was found to be preferentially enriched in the large HDL2b subfraction 
(120) and its enrichment can compromise the anti-inflammatory functionality of HDL 
(37) and increase risk of CVD (244). A reduction in ApoC-III combined with no change 
in HDL2b may suggest an improvement in HDL functionality by the BOLD+ dietary 
pattern.  
One limitation of the current study is that it was not designed as a part of the 
initial BOLD study and had a reduced sample size, which resulted in less statistical 
power. For main effects, we detected diet-induced changes in LDL4 and HDL2b as well 
as total LDL and HDL (data not shown). For the secondary analysis, we failed to detect 
a significant baseline HOMA-IR and diet interaction (P = 0.153) with a mixed model. 
However, by using the median split, we clearly demonstrated the difference in the LDL4 
response pattern to the test diets in the low and high baseline HOMA-IR groups, which 
suggests a likely interaction of HOMA-IR with the DASH and BOLD dietary patterns.  
In the present study, we showed that the proportion of macronutrient may have a 
greater influence than protein source on LDL distribution in a heart healthy dietary 
context. We found that increasing dietary protein at the expense of carbohydrate in a 
heart healthy diet had favorable effects on LDL distribution. A low saturated fat, 
moderate protein diet including lean beef improved the LDL density profile by 
decreasing the absolute and proportional abundance of small dense LDL4 in a mildly 
hypercholesterolemic population. We also offer the first evidence to suggest a possible 
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role for baseline metabolic flexibility in modulating the individual sdLDL response to a 
low saturated fat dietary pattern, and that partial replacement of carbohydrates by protein 
in a DASH-like diet may improve health outcomes for individuals with reduced 
metabolic flexibility. These results combined with previous findings that the BOLD+ 
dietary pattern was the most effective in decreasing ApoB and systolic blood pressure 
merit further investigation on the long term effects of DASH-like, moderate protein 
diets. 
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CHAPTER V 
CONCLUSIONS 
 
We evaluated the health benefits of beef consumption in moderate and low fat 
dietary context in 2 healthy populations.  
In the first study (Chapter II, III), the objective was to evaluate the consumption 
of moderate fat ground beef consumption on HDL density distribution, composition and 
functionality. Our primary findings were that, beef consumption improved metabolic 
flexibility as judged by decreased HOMA-IR score, increased HDL3 S1P and decreased 
HDL 5-KETE regardless of ground beef MUFA:SFA ratio. Though we did observe 
some additional health benefits for high MUFA beef, the effect was mild with no 
significant endpoint difference between low and high MUFA beef observed. These 
findings suggest that the improvements in ASCVD risk by ground beef consumption was 
at least partially mediated by the lean portion of beef, which leads us to the second 
study. 
In the second study (Chapter IV), the objective was to evaluate the effects of lean 
beef as a main protein source in a DASH-like, heart healthy dietary context on 
lipoprotein density distribution. The primary finding was that the small dense LDL4 was 
only significantly decreased by the BOLD+ diet, which contains the highest proportion 
of protein (including lean beef) among the 4 intervention diets. 
Epidemiologic evidence regarding the impact of red meat consumption on 
ASCVD remains mixed. Confounders such as sodium and nitrate (processed meat), total 
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SFA intake and serving size, incorporation in a western dietary pattern may influence 
risk assessment. In our two randomized cross-over beef intervention studies in two 
healthy populations, we observed no adverse effects of 4-5 ounce, unprocessed, low-
moderate fat beef consumption on ASCVD risk. Importantly, we observed high inter-
individual variation in response, especially with advanced lipid assessment. We have 
demonstrated that individual response to beef intervention is influenced by baseline 
health status, with more favorable response observed in subject with better metabolic 
health. Genetic and metabolic typing studies in the future will vastly improve our 
understanding of the underlying mechanisms. 
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